Survival of Bifidobacterium in milk and during simulated gastrointestinal tract transit by Ng, Ean-Chee
Retrospective Theses and Dissertations Iowa State University Capstones, Theses and Dissertations 
1-1-2006 
Survival of Bifidobacterium in milk and during simulated 
gastrointestinal tract transit 
Ean-Chee Ng 
Iowa State University 
Follow this and additional works at: https://lib.dr.iastate.edu/rtd 
Recommended Citation 
Ng, Ean-Chee, "Survival of Bifidobacterium in milk and during simulated gastrointestinal tract transit" 
(2006). Retrospective Theses and Dissertations. 19100. 
https://lib.dr.iastate.edu/rtd/19100 
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and 
Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses 
and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, 
please contact digirep@iastate.edu. 
Survival of Bifidobacte~ium in milk and during simulated 
gastrointestinal tract transit 
by 
Ean-ghee Ng 
A thesis submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
MASTER OF SCIENCE 
Major: Food Science and Technology 
Program of Study Committee: 
Terri D. Boylston, Major Professor 
Aubrey F. Mendonca 
Donald C . B eitz 
Iowa State University 
Ames, Iowa 
2006 
Copyright ©Ean-Ghee Ng, 2006. All rights reserved. 
11 
Graduate College 
Iowa State University 
This is to certify that the master's thesis of 
Ean-Ghee Ng 
has met the thesis requirements of Iowa State University 
Signatures have been redacted for privacy 
111 
~iis thesis is dedicated with Cove to my parents, Swee ~eon~ andSoo fan, who have made aCCmy 
achievements possi6Ce and to the memory of my 6e~oved fate brother, rEn-Sean.. 
iv 
TABLE OF CONTENTS 
ABSTRACT 
INTRODUCTION 
LITERATURE REVIEW 
Vl 
1 
5 
Probiotic Bacteria 5 
Health Benefits of Probiotic Bacteria 7 
Diarrhea 7 
Inflammatory bowel diseases 11 
Lactose intolerance 13 
Atopic diseases 14 
Hypercholesterolemia 15 
Cancer prevention 16 
Bifidobacterium 18 
History 18 
Characteristics of Bifidobacterium 18 
Bifidobacterium species 19 
Incorporation of Bifidobacterium into foods 20 
Challenges 22 
Bifidobacterium growth factors 26 
Incorporation of Bifidobacterium into yogurt and fermented milk 28 
MATERIALS AND METHODS 31 
Bifidobacterium Culture Preparation 31 
Preparation of Samples 32 
Preparation of Supplements 32 
Simulated Gastric Juice and Bile Solutions Preparation 33 
Microbial Analysis 33 
Survivability of Bifidobacterium in milk 33 
Survivability of BifidobacteYium in simulated gastrointestinal tract transit 34 
Lactose Content 35 
Statistical Analysis 36 
Study 1: Survivability of Bifidobacterium strains in milk 36 
Study 2: Effect of inoculation levels on the survivability of B. bifidum 
R0071 in milk 36 
Study 3: Effect of supplements on the survivability of B. bifidum R0071 
in milk 3~ 
V 
RESULTS 3 8 
Study 1: Effect of Bifidobacterium Strains on Viability in Milk and during 
Gastrointestinal Tract Transit 3 8 
Study 2: Effect of Inoculation Levels on Viability of B. bifidum R 0071 in Milk 
and during Gastrointestinal Tract Transit 41 
Study 3 : Effect of Supplements on the Survivability of B. bifidum R0071 in Milk 
and during Gastrointestinal Tract Transit 43 
DISCUSSION 45 
Effect of Bifidobacterium Strains and Inoculation Levels in Milk 45 
Storage stability 45 
Survivability in simulated gastric juice 46 
Survivability in simulated bile solutions 48 
Lactose Content 50 
Effect of Supplements on the Survivability of B. bifidum R0071 in Milk 51 
Whey protein concentrate 51 
Fructooligosaccharides 52 
FIGURES 53 
CONCLUSIONS 58 
APPENDIX A 61 
Effects of Supplements on the Survivability of Bifidobacteria longum in Milk 61 
APPENDIX B 64 
Quality of Milk Packaged in Polylactic Acid and Polyethylene Terephthalate 
Bottles 
REFERENCES 
AC~:NOV'VLEDGEMENTS 
64 
67 
86 
V1 
ABSTRACT' 
The nutritional value of milk can be improved through the incorporation of 
Bifidobacterium. The objective of the study was to evaluate the viability of Bifidobacterium 
in milk and simulated gastrointestinal tract transit and lactose utilization during refrigerated 
storage. Three experiments were conducted. Bifidobacterium infantis, Bifidobacterium 
longum, Bifidobacterium breve and Bifidobacterium bifidum were inoculated into milk at 
108 CFU/mL and viability in milk and simulated gastrointestinal tract transit and lactose 
utilization were studied in the first experiment. In the second experiment, B. bifidum was 
inoculated at 104, 105, and 106 CFU/mL to determine the effect of inoculation level. Finally, 
milk inoculated with 106 CFU/mL B. bifidum was supplemented with 2% and 3% (w/v) 
whey protein concentrate (WPC) or fructooligosaccharides (FOS) to determine the effect of 
supplements. Samples were stored at 4°C for 15 days for ail experiments. Microbial 
viability in milk and lactose content were determined at 3—day intervals. Viability after 4 
hours treatment with simulated gastric juice (pH 3.0) and 1% (w/v) bile solutions at 37°C 
were determined on days 0, 6, 12 and 15. Samples were plated on MRSC agar and 
incubated anaerobically. Lactose content was determined using an enzyme assay in the first 
experiment. 
Survivability in milk over storage period was not significantly different among each 
strain (p<0.05). B. bifidum had a significantly lower survival rate after treatment with bile 
solutions at day 15 (p<0.05). However, microbial counts exceeded 106 CFU/ml for all 
strains during storage and after simulated gastrointestinal transit. Only B. bifidum 
hydrolyzed lactose, and, at day 15, 31 %lactose hydrolysis was observed. No significant 
Vll 
changes in viability of B. bifidum inoculated at 104-106 CFU/mL occurred during storage 
and simulated gastrointestinal transit. Viability of B. bifidum was not affected significantly 
by WPC supplement. ~'OS affected the viability of B. bifidum in milk with significantly 
lower counts on day 12 and 15 and a better survival after treatment with bile solutions at 
day 15 for samples supplemented with 2% FOS (p<0.05). 
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INTRODUC'T'ION 
Bifidobacterium are widely used as probiotic microorganisms to develop functional 
foods. Bifidobacterium are gram positive, anaerobic microorganisms that are normal 
inhabitants in the human colon. In the past few years, Bifidobacterium have been associated 
with several health benefits including the inhibition of pathogenic bacteria such as 
Escherichia. coli 0157:~I7, improvement of lactose tolerance in lactose malabsorption 
individuals, prevention or treatment of diarrhea, decreased incidence of childhood atopic 
diseases, reduction of serum cholesterol levels and, possibly, prevention of colon cancer 
(Brady and others 2000; Marteau and Boutron-Ruault 2002; Ouwehand and others 2002; Lin 
2003; Bergonzelli and others 2005; Sullivan and Nord 2005). Over the past few years, with 
the increased demand for healthy foods beyond their nutritional value and the health benefits 
claimed by Bifidobacterium, functional foods with the incorporation of viable 
Bifidobacterium have been extensively studied and developed (Scheinbach 1998). 
To obtain the claimed health benefits, the functional food must contain viable 
Bifidobacterium with at least 10~ CFU/g or mL of the product, which is a challenge because 
Bifidobacterium are anaerobic microorganisms and are relatively sensitive to a low pH 
environment (Ross and others 2005). Therefore, not all food systems are a suitable 
environment for the survival of Bifidobacterium and challenges have to be overcome to 
produce functional foods that maintain a sufficient amount of viable Bifidobacterium 
throughout the shelf life of the food (Saarela and others 2000; Biavati and others 2000). For 
this reason, an intensive research effort has focused on protecting the viability of the 
Bifidobacterium during product manufacture and storage. Studies with yogurt and fermented 
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milk have demonstrated that the viability of the Bifidobacterium can be enhanced by 
supplementing those products with whey protein concentrate or fructooligosaccharides 
during the fermentation process (Gibson and Wang 1993; Bruno and others 2002; ivlartin- 
Diana and others 2003; Akalin and others 2004; Janer and others 2004). 
In addition to the stability of Bifidobacterium throughout the shelf life of the food, 
survivability of the organism during gastrointestinal tract transit is another challenge. In 
order to deliver the beneficial effects, Bifidobacterium have to survive through the 
gastrointestinal tract transit in sufficient amounts to be effective. Gastric juice in the stomach 
and the action of bile salts in the intestine are harsh conditions for the survivability of the 
Bifidobacterium (Bezkorovainy 2001). Acidity in gastric juice and the antimicrobial action of 
the bile salts cause damage to the cells and thus decrease their viability. 
Several different approaches have been taken to increase the survivability of 
Bifidobacterium during gastrointestinal tract transit. Microencapsulation of Bifidobacterium 
cells in carrier materials, such as cellulose acetate phthalate, gelatin, soluble starch, skim 
milk and gum arabic, resulted in increased viability when treated with simulated pH 2.0 
gastric juice and 2.0% (w/v) bile salts in comparison to the free cells (Rao and others 1989; 
Liars and others 2003). Immobilization of Bifidobacterium cells in calcium alginate beads and 
gellan—xanthan beads showed a significantly better survival when treated with simulated 
gastric juice as well (Lee and Heo 2000; Sun and Griffiths 2000). Although these novel 
technologies seem promising, the production cost maybe ineffective. The more economical 
way to deliver Bifidobacterium to the consumer is to develop Bifidobacterium supplemented 
food. Studies has shown that Bifidobacterium in fermented milk have increased survivability 
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in simulated gastric juice treatment and in vivo gastrointestinal tract transit (Berrada and 
others 1991; Pochart and others 1992). 
Incorporation of Bifidobacterium into dairy products has been extensively studied. 
Cheese, yogurt, fermented milk and fresh milk with Bifidobacterium are widely available in 
the market. Milk is an excellent carrier medium for the delivery of Bifidobacterium into the 
human gut. Milk proteins function as buffering agents and protease inhibitors and thus help 
to protect the Bifidobacterium during the upper gastrointestinal tract transit (Charteris and 
others 1998). Moreover, the addition of milk protein to the gastric juice will increase the pH 
of the gastric juice and, hence, provide a more favorable environment for the survivability of 
the Bifidobacterium. In addition, adhesions of the microorganisms to human intestinal cells 
are critical in order to permanently establish Bifidobacterium in the human gut. Survivability 
and adhesion of the probiotic bacteria to human intestinal cells are improved with milk as the 
carrier (Conway and others 1987). 
The overall objective of our study was to examine the viability of Bifidobacterium 
spp. inoculated into milk over a 15—day storage period and their survivability after simulated 
gastrointestinal tract transit. In this study, only Bifidobacterium species found in human were 
usedl. In order for humans to obtain the health benefits of Bifidobacterium, it is recommended, 
based on scientific beliefs, that human strains are consumed (Saarela and others 2000). 
In the first study, the survivability and lactose utilization rate of B. infantis R0033, B. 
longum R0175, B. breve R0070 and B. bifidum R0071, inoculated at 81og10CFU/mL, were 
evaluated. In the second study, the Bifidobacterium strain with the highest lactose utilization 
rate was selected and inoculated at lower concentrations, 4, 5, and 6loglo CFU/mL. The 
effects of the inoculation levels on their survivability over the storage period and during 
4 
simulated gastrointestinal tract transit were evaluated. Finally, whey protein concentrate and 
fructooligosaccharides supplements were added to the milk and the effects of the 
supplements on the survivability of B. bifidum during the starage study and after the 
simulated gastrointestinal tract transit were evaluated. 
The hypothesis of this study is that Bifidobacterium strains, inoculation levels and the 
addition of supplements will affect the viability of the Bifidobacterium in milk and simulated 
gastrointestinal tract transit during a 15—day storage period, and Bifidobacterium will utilize 
the lactose in the milk. 
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LITERATURE REVIEW 
lProbiotic bacteria 
The consumption of fermented dairy products has a long history that dates back to 
many centuries ago even before the discovery of microorganisms (Fuller 1992). It was one of 
the oldest methods used to preserve and produce foods (Leahy and others 2005). In pre-
biblical times, humans consumed fermented products and the health claim stated in the 
Persian version of the Old Testament (Genesis 18:8) was that "Abraham owed his longevity 
to the consumption of sour milk." In 76 BC, fermented milk products were used 
therapeutically by Roman historian, Plinius, to treat gastrointestinal diseases (Schrezenmeir 
and de Vrese 2001). However, the concept of probiotics did not emerge until the early 1900s 
when Eli Metchnikoff in Pasteur Institute in Paris discovered the benefits of lactobacilli. 
Metchnikoff (1907), the Russian born Nobel Prize recipient, recognized the positive roles of 
probiotics and suggested that "The dependence of the intestinal microbes on the food makes 
it possible to adopt measures to modify the flora in our bodies and replace the harmful 
microbes by useful microbes". In addition to Metchnikoff's finding, Henry Tissier, a French 
pediatrician, discovered lower counts or the absence of Y—shaped bacteria in infants with 
diarrhea compared to healthy infants. Tissier then proposed that the consumption of these 
"bifid" Y—shaped bacteria could help to restore the healthy gut flora and possibly treat 
diarrhea. Metchnikoff and Tissier's findings and publications in early 1900s increased the 
scientific interest in probiotics (Basic and Kurmann 1983). However, the results were not 
always positive and the findings were subjective. Thus, the probiotic concept was regarded as 
not scientifically proven. 
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In the past two decades, the improvement in the identification and isolation of 
probiotic cultures has consequently helped to provide evidence that support the health claims 
related to the consumption of probiotics. The increased Interest in consuming probiotics has 
drawn the attention of the World Health Organization (WHO) and the Food and Agriculture 
Organization (FAO) of the United I`lations and resulted in the definition of the term probiotic. 
probiotic was originally derived from the Greek language and means `for life' . In 1965, Lilly 
and Stillwell was the first to introduce the term probiotic as "substances secreted by one 
microorganism which stimulate the growth of another". The term probiotic has been 
redefined by many other researchers throughout the years, including Parker (1974}, the f rst 
researcher who used the term probiotic in the sense that it is used today. In 2001, in an Expert 
Consultation meeting organized by WFIO/FAO, the definition of probiotic was proposed as 
"live micro-organisms which when administered in adequate amounts confer a health benefit 
on the host". This definition was widely used and in 2002, Marteau and others redefined 
probiotic as "microbial cell preparations or components of microbial cells that have a 
beneficial effect on health and well-being". Even though the definitions of probiotic may 
vary, the benefits of probiotic microorganisms are normally linked to the improvement of 
human health. 
Lactic acid producing bacteria, Lactobacillus and Bifidobacterium, are the most 
common probiotic bacteria that are incorporated into food for therapeutic purposes 
(Roberfroid 2000b). Incorporation of probiotics into food is well accepted by the consumer 
due to their positive association with maintaining a healthy gastrointestinal tract and their 
`generally recognized as safe' (GRAS) status under the Food and Drug Administration (FDA) 
regulation (Svensson 1999; Sullivan and Nord 2005). 
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Health Benefits of Pr®biotic Bacteria 
Numerous clinical studies have identified several different health benefits associated 
with the incorporation of probiotic bacteria into the diet. Prevention of diarrhea, treatment of 
inflammatory bowel diseases, alleviation of the symptoms of lactose intolerance, decreased 
incidence of atopic diseases, possible reduction in the risk of colon cancer, and reduction of 
serum cholesterol have been linked to the consumption of probiotic bacteria (Scheinbach 
1998; Lin 2003; Servin 2004). 
Diarrhea 
Diarrhea has been associated with the disruption of the balance of normal gut 
microflora. Gut microflora possess a quality known as colonization resistance that could help 
to prevent the overgrowth of pathogens in the gut. The disruption of the equilibrium of the 
gut microflora could lead to the overgrowth of pathogenic microorganisms, and the toxins 
produced by these pathogens can cause diarrhea (De Roos and Katan 2000). Probiotic 
bacteria are believed to aid in colonization resistance and restore the balance of the gut 
microflora. Studies have been conducted on the effectiveness of probiotic bacteria on 
minimizing or preventing the risk of infectious diarrhea, traveler's diarrhea, acute rotavirus 
diarrhea and antibiotic—associated diarrhea (Bergonzelli and others 2005; Sullivan and Nord 
2005). 
Infectious Diarrhea 
The use of probiotic bacteria as prevention or treatment of infectious diarrhea has 
been suggested by several research studies. In an in vitro study, Gibson and Wang (1994) 
incubated Bifidobacterium infantis with pathogenic microorganisms, Esche~-ichia coli and 
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Clostridium perfringens in various fermentation systems. The growth of the pathogens 
declined by approximately 0.4 and 0.5 loglo CFU/mL, respectively, even though the pH of 
the growth media was maintained at neutral. In an in vivo study in laboratory animals, Silva 
and others (2004) found that when mice received 1 Og CFU/mL Bif ldobacterium longum 
supplemented in milk in their diet, they had a 40% higher chance of surviving than the 
control mice when salmonella typhimurium (1 O 1 CFU/mL} suspension was fed. Asahara and 
others (2004) showed that mice fed with 10g CFU/mL B breve had a higher survivability rate 
compared with control mice when Shiga toxin-producing Escherichia coli O157:H7 (103
CFU/mL) was fed. Besides inhibiting these pathogens, results from several in vitro and in 
vivo studies have revealed that Bifidobacterium species are effective in inhibiting the 
pathogenic effect or the growth of other pathogens including Listeria monocytogenes, 
Salmonella enterica serovar Typhimurium, Salmonella enteritidis ssp. Typhimurium, 
Clostridium perfringens and Escherichia coli O157:H7 (Silva and others 1999; Asahara and 
others 2001; Toure and others 2003; C7agnon and others 2004). Results from these studies 
suggested that with the consumption of probiotic bacteria, the risk of developing diarrhea 
caused by foodborne pathogens could be minimized. 
Traveler's .diarrhea 
Traveler's diarrhea is one of the most frequently encountered health problems among 
tourists, especially tourists travelling to underdeveloped countries. Tourists travelling from a 
developed country to a developing country have a 20-50% risk of suffering from traveler's 
diarrhea (Ericsson 2003). The most common causes of traveler's diarrhea are the 
enterotoxin producing Escherichia coli, followed by Camp~ylobacter jejuni, Salmonella 
typhimurium, Shigella species and other harmful bacteria and viruses (Dupont and Ericsson 
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1993; Casburn-Jones and Farthing 2004). A study conducted by Hilton and others (1997) 
with Lactobacillus casei rhamnosus GG as the probiotic supplement showed that the 
incidence of diarrhea was lower in the supplemented group. Oksanen and others (1990) 
conducted aplacebo--controlled, double—blinded study on subjects traveling to two different 
destinations in Turkey. A 5.5% lower incidence of diarrhea in the probiotic group, with the L. 
casei rhamnosus GG supplement, compared to the placebo group were observed in tourists 
traveling to Alanya. However, the same effect was not observed in subjects who traveled to 
another destination, Marrnaris, when a similar study was conducted. Even though these 
results showed that probiotics helped in preventing traveler's diarrhea, the methodology- used 
was insufficient and some of the results are not significant. Thus, the evidence for the 
beneficial effects remains unconvincing and no clear conclusion could be drawn (DuPont 
1997). 
Acute l~otavirus Diarrhea 
Acute rotavirus diarrhea is one of the major causes of diarrhea in infants and young 
children and accounts for approximately 45 % of all diarrhea in children worldwide (Sullivan 
2005). Each year, nearly 500,000 children die due to severe rotavirus disease and it is 
estimated that, by age 5, almost every child will have rotavirus diarrhea (Parashar and others 
2003). ~wHO (1995) recommended the use of oral rehydration salts (ORS) to replace the 
fluid and electrolyte losses in treating this disease. Efforts have been made to develop a 
vaccine for this disease; however, before an effective vaccine is available, some preventive 
actions can be taken to reduce the incidence of rotavirus diarrhea in children (Rolfe 2000). 
Research from several large and well-designed clinical trials carried out in Finland, 
Pakistan, Europe, Peru and the ~Jnited States have shown the effectiveness of probiotics 
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supplements in the treatment or prevention of rotavirus diarrhea in children. Guandalini and 
others (2000) added 10`0 CFU/250mL Lactobacillus GG to the ORS for children with acute- 
onset diarrhea. The diarrhea lasted longer than 7 days for 2.7% of the children in the 
probiotic groups compared to 10.7% of the children in the placebo group. Other studies also 
showed that when probiotic bacteria were either given as a supplement or in fermented milk, 
the ri sk of rotavirus diarrhea decreased in healthy children and the duration of diarrhea was 
significantly shortened in the children infected with rotavirus diarrhea (Isolauri and others 
1991; Saavedra and others 1994; Raza and others 1995; Guarino and others 1997; 
Shornikova and others 1997; Oberhelman and others 1999). 
Antibiotic Associated Diarrhea 
Antibiotic—associated diarrhea (AAD) is defined as diarrhea that develops between a 
few hours after the initiation of the antibiotic treatment to six to eight weeks after the end of 
the treatment (Beaugerie and Petit 2004). AAD occurs in 5 to 25% of the patients receiving 
antibiotic therapy, although the reason behind this is not fully understood (Bergogne-Berezin 
2000). Surawicz (2003) suggested that the disruption of the normal gut microflora has 
increased the ri sk of infection with pathogens, such as Clostridium difficile. C. difficile, the 
most common cause of AA.D, accounts for 10-20% of AAD in antibiotic therapy patients. In 
addition, 20% of the hospital patients maybe infected with C. difficile (Bartlett 2002; 
Plummer and others 2004). 
C. difficile colonizes and grows in the human colon and the toxins produced could 
lead to colonic damage. Antibiotic treatment is normally used to treat this infection but the 
recurrence of the infection after the therapy is very common (Surawicz 2003). Barbut and 
others (2000) estimated that within 2 months after the first episode of C. diffacile infection, 
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patients will have 1 S-3 S %risk of re—infection. The use of probiotics is recommended to 
restore the normal gut microflora to prevent the re—infection. Plummer and others (2004) 
studied patients receiving antibiotic therapy with both Bifidobacte~ium and Lactobacillus or 
placebo as supplements. Lower risks of developing diarrhea were observed in the group 
receiving both BifidobacteYium and Lactobacillus as supplements compared to the control 
group who received a placebo as a supplement. In addition to this study, additional research 
with different strains of probiotics, such as Bifidobacterium longum, Lactobacillus GG and L. 
casei GG showed a significant effect on the prevention and treatment of AAD (Colombel and 
others 1987; Siitonen and others 1990; Young and others 1998). 
The mechanisms of how probiotic bacteria function on the prevention of diarrhea are 
not fully understood. The production of acid, hydrogen peroxide or antimicrobial agents, and 
the competition for adhesion receptors and nutrients might play an important role (Servin 
2004). 
Inflammatory bowel diseases 
Inflammatory bowel diseases (IBD) are referred as ulcerative colitis, Crohn's disease 
and pouchitis (Lin 2003). Genetic susceptibility, environmental factors and immune 
dysregulations are the underlying causes of IBD. Even though these are the main factors that 
cause IBD, the colonization of pathogenic bacteria is required to express the disease fully 
(Shanahan 2002). Currently, antibiotic treatment is the commonly applied treatment for IBD 
patients. However, antibiotic treatment is not encouraged for the treatment of uncomplicated 
IBD patients (Feagen 1997) and chronic use of antibiotic treatment can lead to toxicity, side 
effects, risks of bacterial resistance and overgrowth of bacteria in the patients (Shanahan 
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2004). Therefore, the alteration of the gut microflora is a more promising way to treat IBD 
patients. 
Studies using anon-pathogenic strain of Escherichia coli have shown to be as 
effective as mesalazine in treating ulcerative colitis patients, these results have further 
increased the interest in the use ofnon-pathogenic bacteria to replace antibiotic treatment in 
IBD patients (Kruis and others 1997; Rembacken and others 1999). Investigators in several 
animal model studies and human trials demonstrated the possible use of probiotics in treating 
IBD. O'Mahony and others (2001) studied interleukin-1(}—deficient mice with Lactobacillus 
salivarius supplemented in their diet compared with control non-probiotic fed mice. A lower 
histological index score on the ileum, caecum and colon tissues, based on degree of 
inflammation, was scored by the probiotic fed mice compared with the control mice. 
Gionchietti and others (2000, 2003) developed a new probiotic therapy, VSL#3, tc~ 
treat the onset of acute pouchitis and chronic pouchitis. VSL#3 is a highly concentrated 
probiotic therapy with eight different strains of lyophilized probiotic bacteria, which 
consisted of 4 strains of Lactobacillus, 3 strains of Bifidobacterium and 1 strain of 
Streptococcus at 3 x 10~ 1 cells per gram of live microorganisms. Acocktail of probiotic 
bacteria is recommended compared with the use of single strains of probiotic bacteria 
because one strain of probiotic bacteria might work on certain patients or on a certain phase 
of the disease in a patient but not others (Bengmark 1996). Results of adouble—blinded, 
placebo—controlled trial was conducted and the results showed that treatment with VSL#3 
were effective in preventing the onset of pouchitis and improved the quality of life inpatients 
with iieal pouch—anal anastomosis. Even though the results from the clinical trials seemed 
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promising in treating IBD, more large scale clinical trials are needed before VSL#3 can be 
prescribed to other IBD patients. 
Lactose intolerance 
Lactose is the main carbohydrates found in milk. Vesa and others (2000) showed that 
two—thirds of the world population suffers from lactose intolerance or lactose maldigestion. 
Lactose intolerance individuals lack or have a lower amount of (3-galactosidase enzyme (De 
Vrese and others 2001), which functions to break down lactose into glucose and galactose. 
Undigested lactose draws water into the intestine and the fermentation of the lactose by gut 
microorganisms produces acid and gases. Consequently, bloating, cramping and diarrhea 
occur.in lactose intolerance individuals and thus discourage them from consuming dairy 
products (Marteau and others 1997). 
Improvement of lactose digestion in lactose intolerant individuals after the 
consumption of probiotics and lactose has been demonstrated by several research studies. In 
fact, alleviation of the discomfort in lactose intolerance individuals is probably one of the 
well established health claims from the consumption of Bifidobacterium (Scheinbach 1998). 
Marteau and others (1990) measured breath hydrogen content of lactose maladsorption 
individuals who consumed 18 g of lactose in the form of whole milk, yogurt and heated 
yogurt. Bacterial lactase activity was present at 1.7 N/g in yogurt, at 0.3 N/g in heated 
yogurt, and at 0 N/g in whole milk. Results indicated that the subjects digested lactose better 
in the form of yogurt, followed by heated yogurt and then milk. Studies conducted by Jiang 
and others (1996, 1997) showed that Bifidobacterium longum has a positive impact on 
improving lactose digestion in lactose intolerant individuals. The improved lactose digestion 
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may be attributed to the presence of ~3-galactosidase in the probiotic bacteria. Bile salts in the 
small intestine lyse the bacteria upon ingestion and (3-galactosidase contained in the probiotic 
bacteria are released into the small intestine to degrade lactose (De Vrese and others 2001). 
Atopic diseases 
Atopic diseases, such as atopic eczema, allergic rhinitis and asthma, are disorders that 
are commonly observed in the industrialized countries. The incidence of these allergy 
diseases has increased rapidly during recent decades (Kim and others 2005). In 1989, 
Strachan proposed the "hygiene hypothesis" that stated that with the improved hygiene in the 
developed countries and lack of infections in early life, children have a lower immunity and 
thus increased chances of atopic diseases. Several experimental studies had shown that 
stimulating the immune system with certain microorganisms might prevent or treat atopic 
diseases (Maj amaa and Isolauri 1997; Matricardi and others 2003). 
In adouble—blind, randomized placebo controlled study conducted by Kalliomaki and 
others (2001), Lactobacillus GG was given to an expecting mother with at least one first 
degree relative with atopic diseases two to four weeks before delivery, and to the infants for 
six months after birth. The results showed that the development of atopic eczema in the 
probiotic group was 50% lower than the placebo group. Isolauri and others (2000) 
supplemented the diets of infants with atopic eczema with Bifidobacterium lactis or 
Lactobacillus CG and evaluated the severity of their atopic eczema with SC~ring Atopic 
Dermatitis (SCORAD) method. After two months, signif cant reduction in the severity of 
atopic eczema was observed by comparing the SCOR.AD score in infants who consumed B. 
lactis (0-3.8) or L. GG (0.1-8.7) to the unsupplemented group (4.5-18.2). 
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Evidence supporting the use of probiotics in the prevention and treatment of atopic 
diseases are preliminary and inconclusive. Therefore, more extensive studies and clinical 
trials are essential. 
Hypercholesterolemia 
Cardiovascular diseases have been the leading causes of death and accounted for 58% 
and 37.3% of all deaths in the United States in 2002 and 2003 (Thom and others 2006). 
Hypercholesterolemia and high Levels of serum cholesterol in humans, have been linked to 
the development of cardiovascular diseases. Diet is recognized as one way to control serum 
cholesterol levels. Several animal and human research studies showed that incorporating 
probiotic bacteria into the diet could reduce serum cholesterol (Rasic and others 1992; DP 
Smet and others 1998; Kie131ing and others 2002). Xiao and others (2003) studied serum 
cholesterol Levels in adult male volunteers after an intake of 300mL of low fat drinkable 
yogurt with and without =10gCFU/mL BifidobacteYzum longum supplementation for 4 weeks. 
A significant decrease in total cholesterol, 13.7 mg/dl, was observed in the ~. longum group 
especially in subjects with moderate hypercholesterolemia compared to the placebo group 
and before the study (p<0.05). However, some studies have showed no differences or 
improvement in serum cholesterol level when probiotics are given to the subjects (Rossouw 
and others 1981; Thompson and others 1982; De Roos and others 1999). Lin and others 
(1989) conducted adouble—blinded, placebo—controlled study involving 354 human subjects 
with tablets containing 2 X 106 CFU/mL viable L. acidophilus and L. bulgaricus. Four tablets 
per day were consumed for six weeks, and, at the end of the study, no significant differences 
in serum cholesterol were observed between the treatment and placebo group. 
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The differences in the results among these studies maybe due to the use of different 
strains, doses and even the subjects. The exact mechanism on how probiotics aid in reducing 
serum cholesterol is not fully understood. De Smet and others (1 yy4) proposed that probiotic 
bacteria contain active bile acid hydrolase, which hydrolyzes conjugated bile acids, and 
prevents them from being reabsorbed, thus increasing the conversion of cholesterol to bile 
acids. 
Cancer prevention 
Colon cancer is the fourth most common cancer worldwide after lung, breast and 
prostate cancer in both men and women (Boyle and Langman 200). Environmental and 
hereditary factors are the common ri sk factors for developing cancer. Environmental factors, 
such as living area, physical activity, diet and exposure to chemicals, have attracted much 
interest as these ri sk factors are controllable. Numerous results from in vitro studies, in vivo 
animal models studies, epidemiology and human intervention trials have presented evidence 
to support the prevention or treatment of colon cancer by dietary alteration and incorporation 
of probiotic bacteria into the diet. Researchers recommended decreased meat and fat 
consumption and increased dietary fiber and probiotic intake to minimize the ri sk of 
developing cancer (Brady and others 2000). 
In vivo studies have supported the association of diets to the increase mutagenicity in 
the human body (Lidbeck and others 1992; Hayatsu and Hayatsu 1993). Ouwehand and 
others (2002) suggested that diets high in meat and fat or low in fiber tend to cause an 
increase in levels of Bacteroides, Clostridium and other putrefactive bacteria and a decrease 
in levels of Bifidobacterium in the colon. This change in microflora composition has led to an 
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increase in the activity of fecal enzyme, including, ~3—glucuronidase, azoreductase, urease, 
nitroreductase and glycocholic acid reductase, that could convert procarcinogens to 
carcinogens and thus increase the risk of colon cancer. Studies with human volunteers 
conducted by Lidbeck and others (1992) showed that with the consumption ofLactobacillus 
acidophilus, feces and urine mutagenicity decreased when volunteers were fed a fried meat 
diet, which is known to increase feces and urine mutagenicity. In another study conducted by 
Hayatsu and Hayatsu (1993), urine mutagenicity of the volunteers ingesting fried ground 
beef diet also decreased when L. casei was administered orally. 
The incorporation of probiotics into the diets of rats has shown positive results 
(Reddy and Rivenson 1993; Singh and others 1997; McIntosh and others 1999; Tavan and 
others 2002). Tavan and others (2002) demonstrated the protective effect of milk and 
probiotic bacteria on the heterocyclic aromatic amine (HAA) induced colon carcinogenesis in 
rats. Incidence of aberrant crypts were 96% lower in rats with B. animalis—fermented milk 
supplemented diet, 93% lower with S. thermophilus—fermented milk supplemented diet and 
66% lower in the unfermented milk supplemented diet compared with that of the control rats. 
Lyophilized cultures of B. longum were fed to rats to examine the effect of B. longum on 
inhibiting tumor induction by azoxymethane. Ingestion of B. longum significantly suppressed 
the incidence. of colon tumor development and reduced tumor volume and multiplication 
(Singh and others 1997). Reddy and Rivenson (1993) conducted an animal model study by 
inducing tumors in rats with 2-amino-3-methylimidazole[4,5-f7quinoline (IQ). B. longum was 
supplemented into the male rats' diet, and the development of colon tumors was inhibited 
when compared to the control. 
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The mechanisms behind the observed effects of probiotics in preventing cancer were 
discussed by several researchers but it is not well defined (Commane and others 2005). More 
extensive and long-term studies need to be conducted to identify the precise mechanisms of 
action and provide the evidence for the anti-cancer effects of probiotics before their use in 
cancer prevention or treatment in humans can be fully justified. 
Bifidobacterium 
History 
Bifidobacterium was originally discovered and isolated by Henry Tissier around 
1899-1900 when he observed and compared feces of breast-fed infants versus bottle-fed 
infants. He discovered that feces of breast-fed infants have a higher number of irregular Y 
shaped bacterium compared to the bottle-fed infants (Kurmann and Rasic 1991). When 
Bifidobacterium was first discovered, Tissier assigned them to the Bacillus genera. 
Bifidobacterium was then assigned to many different generas included: Bacteroides, Tissieria, 
Nocardia, Lactobacillus, Actinomyces, Bacterium and Corynebacterium (Fooks and Gibson 
2002). In 1924, Orla-Jensen proposed to name these bacteria under different genera, 
Bifidobacterium. This change was in effect in the 8th edition of ~ergey's Manual, which was 
published in 1974 (R.ogosa 1974). 
Characteristics of Bifidobacteriuin 
Bifidobacterium are widely found in the gastrointestinal tracts ofwarm-blooded 
animals. There are human and non-human species of Bif dobacterium. For humans to obtain 
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the health benefits of Bifidobacterium, it is recommended that human strains are consumed 
(Saarela and others 2000). 
Bifidobacterium are gram positive, non-spore forming, non-gas proda~cing and non- 
motile microorganisms with an irregular rod shaped appearance. Bifidobacterium are 
classified as strictly anaerobic microorganisms although their oxygen sensitivity varies 
among species and strains. Bifidobacterium that was isolated from humans have an optimum 
growth temperature of 36-38°C, and optimum pH between 6.5 to 7.0 (Leahy and others 
2005). Acetic acid and L (+}-lactic acid, products of carbohydrate metabolism of 
Bifidobacterium, are produced in a molar ratio of 3:2. 
Bi idobacte~ium species 
Bi~dobacteria bifidum 
B. bi~dum are found in feces of infants, adults and suckling calves, and human vagina. 
Their shapes are highly variable rods. The bacteria are gram positive but may stain 
irregularly when culture ages. They have whitish, opaque, circular, convex shaped colonies 
with a smooth to mucoid surface. B. bifidum has limited fermentation ability, and they do not 
ferment maltose and raffinose. (Rasic and Kurmann 1983; Biavati and others 2000) 
Bi~dobacteria breve 
B. breve are found in feces of infants and suckling calves, human vagina and sewage. 
They are short, slender or thick, and often club—shaped rods. The bacteria are gram positive 
and may autoagglutinate in saline. They have convex colonies with a diameter of 2-3 mm 
and smooth or wavy surface. B. breve do not ferment arabinose or xylose (Reuter 1971; 
Buchanan and Gibbon 1974; Rasic and Kurmar~n 1983; Biavati and others 2000). 
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Bifidobacteria infantis 
B. infantis are found in feces of infants and suckling calves. They are usually small, 
thin, and often spherical orbubble—shaped rods. They often have central granules with no 
branching tendency. The bacteria are gram positive when stained and no clumping is 
observed in saline solutions. Colonies are convex, 2-3 mm in diameter, and exhibit a soft, 
moist consistency. B. infantis do not ferment arabinose, xylose, or mannitol (Reuter 1971; 
Buchanan and Gibbon 1974; Rasic and Kurmann 1983; Biavati and others 2000). 
Bifidobacteria longum 
B. longum are found in feces of infants, adults and suckling calves, human vagina and 
sewage. They are long, curved, club, or swollen—shaped rods. The gram stain results vary but 
are recognized as gram positive. No clumping is observed when treated with saline solutions. 
Thev have convex colonies with 2-5 mm in diameter and shining or slimy surface. B. longum 
ferment pentoses but not gluconate and cellobiose (Reuter 1971; Buchanan and Gibbon 1974; 
Rasic and Kurmann 1983; Biavati and others 2000). 
Incorporation of ~i idobacterium into foods 
Numerous clinical studies have shown that the balance of microflora population in the 
gastrointestinal tract is strongly associated with the overall well-being of an individual. 
Imbalance of the gut microflora can possibly lead to colon cancer, inflammatory bowel 
diseases, diarrhea and other gastrointestinal diseases (Goldin 1986; Salminen and others 1998; 
Saavedra 2001; Marteau and others 2002; Guarner and Malagelada 2003; Servin 2004). 
However, maintaining the balance of the microflora population in the gastrointestinal tract 
has become challenging as our lifestyles have changed with the development of technology. 
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Increases in stress, which consequently increase the demand on the immune system, can 
disrupt the equilibrium of the gut microflora. In addition, changes in the diet and living 
conditions can alter the gut microflora and affect their overall functionality. .Antibiotic 
treatment, which destroys the balance of the gut microflora, can increase the chances of 
infection and colonization by pathogenic microorganisms in the gastrointestinal tract 
(IZambaud and others 1993). The combination of all these factors can shift the balance of the 
gut microflora and thus lead to gastrointestinal—tract related disorders. Therefore, 
maintaining the balance and health of the gut microflora by increasing the number of 
beneficial or health—promoting bacteria, such as Bifidobacterium, in the gastrointestinal tract 
is essential. Incorporation of Bifidobacterium into the diet has been shown to effectively 
increase the number ofhealth-promoting microorganisms in the gut and prevent the 
overgrowth of pathogenic microorganisms (Tannock 2002). 
Nowadays, products with Bifidobacterium are widely available in the market. Freeze—
dried Bifidobacterium is=available in most health food stores or pharmacies as supplements in 
tablets, capsules or powders. A variety of food products supplemented with Bifidobacterium 
are obtainable from the grocery stores, including yogurt, milk, fermented milk, fruit j uices 
and different types of cheeses (Ishibashi and Shimamura 1993; Scheinbach 1998; Chandan 
1999). However, due to the growth requirements of Bifidobacterium, not all food systems are 
suitable to be used as carriers for the delivery of Bifidobacterium to humans. There are 
several challenges that need to be overcome in order to deliver an effective therapeutic dose 
of Bifidobacterium to the consumer via food. 
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Challenges 
The major challenges in incorporating Bifidobacterium into food products and deliver 
their beneficial effects to the consumers are the viability of the bacteria over the storage 
period or the shelf life of the food, their survivability during gastrointestinal tract transit and 
their ability to colonize the gastrointestinal tract to provide the health benefits to the host 
(Saarela and others 2000; Ross and others 2005). The recommended beneficial level or the 
therapeutic dose of Bifidobacterium has not yet been precisely determined but is estimated to 
be between 10~ CFU/g foods to provide the health benefits to the consumer (Ross and others 
2005). Thus, the concentration of the bacteria has to be maintained at this level or above over 
the storage period and the shelf life of the food to be effective (Rambaud and others 1993). In 
addition, some studies had demonstrated that some strains of Bifidobacteriurn do not survive 
well during the transit in the gastrointestinal tract. The acidity of the gastric juice and the 
antimicrobial action of the bile salts can cause damage to the Bifidobacterium (Ibrahim and 
Bezkorovainy 1993; Marteau and others 1993; Lankaputhra and Shah 1995; Charteris and 
others 1998). 
Product and Storage Stability 
Bifidobacterium are incapable of oxygen respiration or growth under aerobic 
condition and thus, they are classified as strict anaerobes (Scardovi 1984). This characteristic 
has become a challenge to the industry when trying to incorporate Bifidobacterium into foods. 
Prevention of oxygen toxicity to the microorganisms during the manufacturing and the 
storage of the food is crucial to deliver foods with viable cells to the consumer. However, the 
sensitivity to oxygen is different between species and between different strains within a 
species (Biavati and others 2000; Talwalkar and Kailasapathy 2003). Some species or strains 
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of Bifidobacterium, for instance, B. infantis, B. longum, B. breve, B. lactis and B. 
pseudolongum are able to tolerate oxygen by limiting their metabolic activity as shown by 
the reduced production of lactic acid under aerobic conditions (Shimamura and others 1992; 
Meile and others 1997; Talwalkar and Kailasapathy 2003). Therefore, selection of the strains 
or species that can tolerate higher oxygen stresses is favorable in order to improve the 
viability of Bifidobacterium after incorporation into food and during the storage and shelf life 
of the food. 
Most species of the Bifidobacterium isolated from human origin have an optimum 
growth temperature of 36-38°C, whereas animal strains have a slightly higher optimum 
growth temperature of 41-43°C. Even though the optimal growth temperature is between 36— 
43°C, a slower growth rate can be observed at a wide temperature range from 25-28°C and 
43-45 °C (Scardovi 1984). Some strains can grow at higher or lower temperature for instance, 
B. theYmacidophilum and B. psychraerophilum which grow at 49.5°C and 4°C, respectively 
(Fong and others 2000; Simpson and others 2004). 
With the wide range of growth temperatures observed for Bifidobacterium, the 
storage temperature of the food is crucial. If the food is stored at room temperature or higher, 
growth of Bifidobacterium in the food might occur and the production of metabolites, such as 
lactic acid and acetic acid may affect the sensory quality of the food (Modler and others 
1990). In addition, foods that require thermal processes will require an additional step to 
incorporate Bifidobacterium into the food because Bifzdobacterium is not a thermoresistant 
microorganism and heating at high temperature will destroy the microorganism (Rasic and 
Kurmann 1983). Without viable cells, the therapeutic effects of consuming the functional 
food cannot be exercised. 
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The optimal pH for the growth and survivability of Bifidobacterium is approximately 
6.5 and 7.0. There is little or no growth observed below the pH range of 4.5 to 5.0 or above 
8.0 to 8.5 (Scardovi 1984), and Bifidobacterium do not survive at pHs above 8.5 (Biavati and 
others 2000). However, the acid tolerance of Bifidobacterium is strain and species specific as 
welt. In milk acidified with lactic acid to pH 4.C, no significant losses in viability of 
Bifidobacterium bifidum and B. longum BL cells were observed after 4 weeks of storage at 
5°C (Vinderola and others 2002). Some strains of Bifidobacterium including B. animalis and 
B. lactis survived exposure to pH 3.5 (Matsumoto and others 2~D04). Nevertheless, the 
inability to grow at lower pHs has limited the use of Bifidobacterium as a starter culture to 
ferment dairy products that have a low final pH, for instance, yogurt, which has a pH 
between 3.7 and 4.3. During the fermentation process, Bifidobacterium utilizes the 
carbohydrates in the food and produces acetic acid and lactic acid. The production of the 
acids decreases the pH in the food system and thus inhibits the growth of Bifidobacterium to 
halt the fermentation process. However, studies had shown that the survivability and growth 
of Bifidobacterium could be improved by acid—adaptation. Acid—adapted B. breve was shown 
to have a greater survivability compared to non—adapted cells (Park and others 1995). 
Gastrointestinal Tract Transit 
In order to obtain the beneficial therapeutic effects from Bifidobacterium, the 
microorganisms have to be able to survive the transit through the gastrointestinal tract and 
reach the colon in high enough quantities to facilitate colonization in the gut (Saarela and 
others 2000). The acidity of the gastric juice and the anti-bacterial action of bile salts are 
critical to the viability of the Bifidobacterium during the gastrointestinal tract transit (Dunne 
and others 1999). The pH of the gastric juice normally ranges from 1.0 to 3.0, which is 
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unfavorable for the survivability of most microorganisms. The concentration of the bile acids 
in bile usually ranges from 0.06% to 2.0%, and bile is harsh on the viability of most 
microorganisms as well (Ibrahim and Bezkorovainy 1993). Results varied when in vitro and 
in vivo tests were performed on the viability of Bifidobacte~ium after exposure to stimulated 
gastric juice and bile solutions. Bifidobacterium strains, such as B. longum 1941 and B. 
pseudolongum 20099, used in a study conducted by Lankaputhra and Shah (1995) showed 
great survivability after treatment with simulated gastric juice and bile salts but B. 
thermophilum 20210 used in their study did not survive as well when the similar treatment 
was applied. Survival studies conducted by other researchers also showed that some 
BifidobacteYium strains survived better than other strains when treated with gastric juice and 
bile solutions (Berrada and others 1991; Clark and others 1993; Clark and. IVlartin 1444; 
Chung and others 1999; Matsumoto and others 2004). Therefore, Bifidobacterium strains that 
are able to tolerate the low pH of the stomach and the antimicrobial effects of bile salts 
produced by the small intestines are preferred for use as dietary adjuncts in food. 
To permanently establish Bifidobacterium in our gut, the ability of the bacteria to 
adhere to the intestinal surface mucosal cells is essential (C7uarner and Schaafsma 1998). 
Adhesion to the intestinal tract allows Bifidobacterium to colonize and grow, and thus shift 
the balance of the microflora in the gut to provide the beneficial therapeutic effects to the 
host. In addition, only adhered bacteria have been thought to effectively induce immune 
effects and stabilize the intestinal mucosal barrier through contact with the gut associated 
lymphoid tissue (Bezkorovainy 2001; Dunne and others 2001). Therefore, Bifidobacterium 
strains with high adhesion properties are preferable because the average survival rate of the 
bacteria after the transit in our gastrointestinal tract has been estimated to be around 30% 
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(Bouhnik and others 1992). Several in vitro studies showed that Bifidobacterium are able to 
adhere to the intestinal mucosal cells however, the adhesion potentials are different among 
different strains (Kirjavainen and others 1998; Perez and others 1998; Tuom~la and Salminen 
1998). For example, B. longum 16 and B. breve 4 used in the study by Bernet and others 
(1993) showed a better adhesion property to human intestinal epithelial Caco-2 cells 
compared to B. bifidum 8 used in the study. 
Bifidobacterium growth factors 
In order to obtain the therapeutic beneficial effects of Bifidobacterium, it is necessary 
that this microorganism survives and grows in the lower gastrointestinal tract. Therefore, 
Bifidobacterium growth factors are commonly added to the food to improve the survivability 
and growth of the bacteria. Whey protein concentrate and fructooligosaccharide are common 
growth factors that are incorporated into food with Bifidobacterium to enharnce the growth 
and viability of the bacteria in the food. 
Whey Protein Concentrate 
Whey protein concentrate (WPC) is an inexpensive and readily available source of 
nutrients generated from the cheese production industry. WPC contains caseinomacropeptide, 
a hydrophilic glycopeptide that contains available nitrogen and amino-sugars that could be 
fermented by Bifidobacterium. In a study conducted by Petschow and Talbott (1990), whey 
fraction of cow's milk and human milk were compared and results indicated that the whey 
fraction of cow's milk promotes the growth of Bifidobacterium as effectively as the whey 
fraction from human milk. Bury and others (1998) showed that with the addition of WPC as 
a nutrient supplement in the whey broth fermentation process, the growth of the probiotic 
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bacteria was higher compared to the control with no WPC supplemented. Numerous research 
studies have shown that with the incorporation of WPC into the fermented milk and yogurt, 
the viability and growth of Bifidobacterium is improved (Janer and others 2004; Martin— 
Diana and others 2003). Sodium dodecyl sulfate—PAGE and amino acid analyses performed 
by Dave and Shah (1998) suggested that the nitrogen source in the form of peptides or amino 
acids from the WPC improved the viability of Bifidobacterium when WPC is added into 
yogurt fermentation. 
Fructooligosaccharides 
Fructooligosaccharides (FOS) are natural carbohydrates that are found in a wide 
variety of fruits, vegetables and cereals (Losada and 011eros 2002). The human body does not 
produce enzymes that can digest FOS. Thus, FOS is classified as anon--digestible 
oligosaccharide as well as dietary fiber (Molis and others 1996; Roberfroid 2000a). 
Undigested FOS transit from the upper gastrointestinal tract into the intestine and colon, and 
Bifidobacterium that are present in the intestine and colon utilize FOS through fermentation 
(Collins and Gibson 1999). FOS has been demonstrated as an effective Bifidobacterium 
growth promoting factors through both in vivo and in vitro assessments. Several in vivo 
studies showed that the incorporation of 8-15g of FOS in the diet increases Bifidobacterium 
counts in the feces (Gibson and others 1995; Guigoz and others 2002; Boehm and others 
2005). In vitro studies by Alkalin and others (2004) also showed that with the addition of 2% 
FOS, the viability and growth of Bifidobacterium animalis and B. longum were enhanced in 
the fermentation process for the production of yogurt. Similar trends were observed in the 
production of fermented milk and batch culture fermentation when FOS is added (Gibson 
and Wang 1993; Bruno and others 2002). 
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Incorporation of Bifidobacterium into yogurt and fermented milk 
Dairy products are one of the most commonly available foods to function as the 
carrier for the delivery of Bifidobacterium into the human gut. Milk, fermented milk, yogurt 
and cheeses with Bifidobacterium are currently available in the market. The buffering 
capacity of milk protein has helped to ensure the survivability of Bifidobacterium during the 
transit in the upper gastrointestinal tract and the low levels of oxygen in milk can promote a 
favorable environment for the survival of the strict anaerobic Bifidobacterium (Klaver and 
others 1993; Charteris and others 1998; Chandan 1999) Thus, the interest of utilizing dairy 
products as vehicles for transferring the probiotics into the human gut has increased and 
extensive research has been performed. 
There is a wealth of research focused on the incorporation of Bifidobacterium into 
yogurt and fermented milk. Bifidobacterium are added into fermented milk and yogurt either 
with the starter culture before the fermentation process or after the fermentation process. The 
addition of Bifidobacterium into the milk before the fermentation process is critical because 
the bacteria may alter the fermentation process and the quality of the final product. In 
addition, the decrease in pH of the yogurt and fermented milk during the fermentation 
process may decrease the viability of the Bifidobacterium in the end product. Besides these 
factors, during low temperature storage, the viability of the Bifidobacterium is affected by the 
low pH of the fermented milk and yogurt (Klaver and others 1993). Therefore, selections of 
Bifidobacterium strains that can tolerate low pH environment are favorable. 
Bifidobacterium is a strict anaerobe and the oxygen levels in yogurt and fermented 
milk may decrease the viability of the bacteria. Ishibashi and Shimamura (1993) have 
developed a solution to ensure the viability of Bifidobacterium during the storage and shelf 
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life of the yogurt. They reported that Streptococcus thermophilus utilizes a large amount of 
oxygen and thus Bifidobacterium can be inoculated with S. thermophil~,cs. The oxygen present 
in the yogurt is then utilized by S. thermophilus and hence the viability of Bifidobacterium is 
enhanced. 
In addition to selecting the Bifidobacterium strains that survive best in the fermented 
milk and yogurt, other techniques have been utilized to enhance the viability and growth of 
Bifidobacterium in the cultured dairy products. The addition of supplements, for instance, 
amino acids, peptides, prebiotics and other micronutrients to increase the survivability and 
growth of the bacteria have been extensively studied. Ascorbic acid and cysteine were added 
into yogurt and fermented milk to decrease the redox potential in the food and provide a 
more favorable environment for the growth of Bifidobacterium (Klaver and others 1993; 
Dave and Shah 1997a, b). However, in the presence of the yogurt cultures, L. delbrueckii ssp. 
bulgaricus and Streptococcus thermophilus, and the fermented milk cultures, L. acidophilus 
Ki and S. thermophilus S3, the viability of the Bifidobacterium was not improved by the 
addition of ascorbic acid and cysteine in these studies. The yogurt and the fermented milk 
cultures decreased the pPI in the milk before the favorable redox potential for the 
Bifidobacterium was achieved (Klaver and others 1993). 
Production of yogurt supplemented with whey protein concentrate, acid casein 
hydrolysate or tryptone enhanced the viability of Bifidobacterium through the addition of 
nitrogen in the form of peptides and amino acids (Dave and Shah 1998). Supplementation of 
fermented goat's milk with whey protein concentrate decreased the fermentation time by 2 
hours and increased the viable counts of Bifidobacterium by 0.7 log units (IVlartin--Diana and 
others 2003). Addition of prebiotics, for instance 2% FMS, into yogurt maintained the 
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viability of B. longum above 106 CFU/mL for 21 days storage time compared to 7 days in the 
control with no FOS supplemented (Alkalin and others 2004). 
The incorporation of Bifidobacterium into other food products has been studied and 
several different approaches have been examined to increase their viability in food and 
during gastrointestinal tract transit. More clinical studies are needed to compare the 
survivability of Bifidobacterium in different food products after the gastrointestinal tract 
transit. 
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MATERIALS AND METHODS 
Bi idobacterium Culture Preparation 
Freeze—dried Bifidobacteria bifidum R0071, B. breve R0070, B. infantis R003 3 and B. 
longum R0175 cultures obtained from Institut RoselULallemand (Montreal, Canada) were 
used throughout the experiments. Freeze—dried powdered cultures were added to 30 mL 
MRSC broth, which is prepared by supplementing MRS broth (Difco Laboratories, Detroit, 
MI, USA) with filter-sterilized 0.05% L-cysteine hydrochloride (Sigma Chemical Co., St. 
Louis, MO, USA) and 0.02% resazurin (Sigma Chemical Co., St. Louis, MO, USA). L—
cysteine was added to MRS broth 24 hours prior to inoculation of the culture to achieve 
reduced conditions in the broth medium for the optimal growth of Bifidobacterium. 
Resazurin was added as an oxygen indicator. In order to achieve a strict anaerobic 
environment, the headspace in each tube of MRSC broth with inoculated Bifidobacterium 
was purged for 30 seconds with nitrogen filtered through glass wool. The purged tubes were 
sealed with butyl rubber stoppers and wrapped with parafilm prior to incubation at 37°C for 
24 hours. 
After 24 hours, 1 mL of each culture, containing approximately 109 CFU/mL, was 
transferred aseptically into fresh 30 mL MRSC broth, purged with nitrogen and sealed with 
butyl rubber stopper and parafilm. The cultures were incubated at 3 7°C for 20 hours. Gram 
stain was performed and the characteristics of the bacteria were identified microscopically. 
After 20 hours, 1 mL of each culture was transferred into 200 mL of fresh MRSC broth, 
nitrogen purged, sealed with parafilm and incubated at 37°C for 20 hours. 
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Preparation of Samples 
Cells were harvested by centrifugation (Sorvall, Newton, CT, USA) at 10,000 X g for 
10 minutes at 4°C. Supernatant was discarded and pellets of harvested cells were washed by 
suspending the pellet into 200 mL of sterile 0.85% saline solution. Saline solution was 
removed after centrifugation (10,+000 X g for 10 minutes at 4°C) of the cell suspension. 
Pellets of Bifidobacterium cells were then suspended into 200 mL of commerciallyT available 
2% milk (Hyvee, Des Moines, IA, USA). The final concentration of Bifidobacterium 
obtained was approximately 91og10 cfu/mL. 
In order to obtain 200 mL of 8 logs o CFU/mL Bifidobacterium milk sample, 20 mL of 
9 loglo CFU/mL Bifidobacterium milk samples were aseptically transferred into 180 mL of 
fresh milk. Different inoculation levels were prepared by diluting 9 logo C;FU/mL 
Bifidobacterium milk samples with the appropriate amount of milk aseptically. Separate 
samples were prepared for each sampling day. Samples were stored in 4°C v~alk—in cooler. 
Preparation of Supplements 
whey protein concentrate (wPC; Instantized WPC 8010, Hilmar Ingredients, 
Oakland, CA, USA) and fructooligosaccharides (FOS; BeneoTM P95, ORAFTI, Malver, PA, 
USA) were vacuum packaged and sterilized by irradiation at 40 kiloGray. Stock solutions of 
WPC and FOS were prepared by dissolving 70 g of each supplement in 280 mL of milk (w/v) 
aseptically. In order to prepare a 2% supplemented samples, 16 mL of the supplement were 
added into 184 mL Bifidobacterium milk samples; 24 mL of the supplement were added into 
176 mL Bifidobacterium milk samples to prepare a 3% supplemented samples. Samples were 
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inverted 3 times to obtain homogeneous samples. Separate samples were prepared for each 
sampling day. Samples were stored in 4°C walk—in cooler. 
Simulated Gastric Juice and Bile Solutions Preparation 
Simulated gastric juice and bile solutions were prepared according to Lian and others 
(2003). In this study, pH 3.0 was selected for gastric juice and 1 %concentration was selected 
for bile solutions. 
Simulated gastric juice was prepared by suspending 1.5 g of pepsin (Fisher Scientific, 
Fairlawn, NJ, USA) in 500 mL of 0.5% saline solution. The simulated gastric juice was 
adjusted to pH 3.0 with 12 N hydrochloric acid (HCl) (Fisher Scientific, Fairlawn, NJ, LISA) 
and sterilized by membrane filtration (0.45 µm) (Fisher Scientific, Fairlawn, NJy USA). 
Sterilized simulated gastric juice (10 mL) was pipetted aseptically into sterilized cap tubes. 
Bile solutions (1 %) were prepared by suspending 1 g of oxgall (Difco Laboratories, 
Detroit, MI, USA) into 99 ml of distilled water. Bile solution (10 mL) was pipetted into cap 
tubes and sterilized by autoclaving at 121 °C for 15 minutes. Both simulated gastric juice and 
bile solutions tubes were stored at 37°C prior to the experiments. 
Microbial Analysis 
Survivability of Bifidobacterium in milk 
Survivability of Bifidobacterium in milk samples were determined at 3—days intervals 
throughout the 15~1ay storage period. At each sampling day, 1 bottle of the milk samples 
was removed from the walk-in cooler and inverted 20 times to obtain a homogeneous sample. 
One mL of the milk samples was serially diluted with 9 mL of sterilized 0.1 %peptone water 
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to obtain dilutions ranging from 10-2 to 10-~. Samples of appropriate dilutions were spread 
plated on MRSC agar (MRS agar with 0.05°~o L—cysteine hydrochloride). Control milk 
samples with no BifidobacteYium inoculated were plated on MRSC to determine the counts 
of background microflora on each sampling day. 
Each sample with appropriate dilutions was spread plated in duplicate. Plates were 
incubated in anaerobic jars with AnaeroGen~ 3.5 L gas packs (Oxoid, Inc., Bashingstroke, 
Hampshire England) at 3 7°C for 72 hours. Colonies on each plate were counted, averaged, 
and expressed as log colony—forming units per mL sample (log CFU/mL). Colonies were 
gram stained and analyzed microscopically to confirm the identity of the bacteria. 
Survivability of Bi idobacte~ium in simulated gastrointestinal. tract transit . 
Simulated gastrointestinal tract transit survivability assays were performed on 
Bifidobacte~ium milk samples on days 0, 6, 12 and 15 by using simulated gastric juice and 
bile solutions. Ten mL of Bifidobacterium milk sample was added into cap tubes containing 
10 mL of sterilized simulated gastric juice. Samples were vortexed and incubated in a 37°C 
water bath for 4 hours. After 4 hours, samples were vortexed and serial dilutions were 
performed with 9mL of sterilized 0.1 %peptone water. Cell enumerations were determined 
by using the spread plate method on MRSC agar. Appropriate dilutions were used and plates 
were incubated at 37°C for 72 hours anaerobically. The survivability of Bifidobacterium in 
the bile solutions was tested by using the same procedure conducted for the simulated gastric 
juice. The survivability of Bifidobacterium during simulated gastrointestinal tract transit was 
expressed as % survivability by dividing the count after ~ hours with the count at the day of 
analysis and multiplied by 100%. 
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Lactose Content 
Lactose content was measured at 3—day intervals throughout the 15—day storage 
period. Megazyme lactose and D-galactose (rapid) assay kits (Megazyme International 
Ireland Ltd., Bray, Ireland) were used, and milk without Bifidobacterium was used as a 
control. Samples were extracted by adding 1 mL of milk samples into 100 mL volumetric 
flask containing 60 mL distilled water. Samples were held at 50°C with occasional swirling 
for 15 minutes. Carrez I solution (2 mL) and Carrez II solution (2 mL) were added with 
mixing after each addition. Sodium hydroxide solution (4 mL, 100 mM) was then added and 
mixed vigorously. Samples were diluted to the mark with distilled water and mixed. 
Whatman No. 1 filter papers were used to filter the samples. The first few mL of the samples 
were discarded, and the clear filtrate was used in the assay. 
Samples were treated with (3—galactosidase to hydrolyze the lactose into B—glucose 
and D—galactose. Galactose mutarotase were added to interconvert a—D—galactose to (3—D— 
galactose. R-galactose dehydrogenase and NAD+ were added to oxidize (3—D—galactose to D— 
galactonic acid and form NADH. The amount of NADH formed (mol) is equivalent to the 
amount of lactose present in the samples. The concentration of NADH was measured by 
using a spectrophotometer (Spectronic Genesys 10, Thermo Electron Co., Waltham, MA, 
USA) at 340 run wavelength. Duplicate measurements were conducted for each sample. 
Lactose content of the samples was calculated and results were expressed as gram lactose/mL 
milk. 
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Statistical Analysis 
The experiments were designed as 2—way factorials with treatment and storage time 
as the main factors. The experiments were conducted in duplicate. Data were anatyLed by 
analysis of variance (AI~TOVA) using Statistical Analysis System software program's (SAS 
Institute Inc., Cary, NC) General Linear Model (GLM) to determine the significance of main 
factors and interactions between main factors. Differences between factors were determined 
using Tukey's honestly significant differences test. The level of significance was set at 
p<0.05. 
Study 1: Survivability of Bifidobacterium strains in milk 
The experiment was designed as a 2—way factorial with the Bifid~bacterium strains, B. 
bifidum R0071, B. breve R0070, B. infantis R0033 and B. longum R0175 and storage time as 
the main factors. Each Bifidobacterium strain was inoculated at 108 CFU/mL and stored for 
15 days in 4°C walk—in—cooler. Viability of the Bifidobacterium strains in milk and after 4 
hour—simulated gastrointestinal tract transits were studied. Lactose content was measured. 
Study 2: Effect of inoculation levels on the survivability of B. bifidum R0071 in milk 
B. bifidum R0071 was selected for this experiment and inoculated into milk at 3 
different inoculation levels, 104, 105 and 106 CFU/mL. Viability over the storage period and 
after the 4hour—simulated gastrointestinal tract transit was studied. Effect of inoculation 
level and the storage time on viability of the B. bifidum R0071 was analyzed in this 
experiment. 
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Study 3: Effect of supplements on the survivability of B. bifidum R0071 in milk 
B. bifidum R0071 was inoculated into the milk at 106 CFU/mL. Samples were 
supplemented with 2 or 3%WPC or FOS. Supplements and storage time were the main 
factors in this experiment. B. bifidum R0071 viability over the storage time and after the 4 
hour—treatment with simulated gastrointestinal tract transit was studied. The effects of the 
treatment and the storage time on the viability of the B. bifidum R0071 were analyzed. 
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RESULTS 
Milk samples without Bifidobacterium were plated on MRSC agar and incubated 
anaerobically at 37°C for 72 hours on each sampling day to determine the counts of 
background microflora. The background microflora in these three studies throughout the 15— 
day sampling time was less than 102 CFU/mL (results not shown). The amount of 
Bifidobacterium present in the samples in each study was greater than 104 CFU/mL. The 
dilutions performed in these studies diluted out the background microflora that might be 
present in the milk samples. Therefore, the counts obtained from the Bifidobacterium milk 
samples throughout the studies were not affected by the background microflora. 
Study 1: Effect of Bifidobacterium Strains on ViabiliTy in Milk amd during 
Gastrointestinal Tract Transit 
Survivability of the four Bifidobacterium strains, B. infantis R0033, B. longum R0175, 
B. breve R0070 and B. bifidum R0071 during the 15—day storage period at refrigeration 
temperature, 4°C, is illustrated in Figure 1. The bacteria were inoculated at approximately 8 
loglo CFU/mL into 2% fat milk. Satisfactory cell survivability with no log reduction greater 
than 1 logo CFU/mL was observed for all the Bifidobacterium strains used in this study over 
the 15—day storage period. The interaction between the strains and the storage time was not 
significant. The log reduction at day 15 compared to day 0 for the four Bifidobacterium 
strains, B. infantis R0033 (0.571og10 CFU/mL), B. longum R0175 (0.201ogio CFU/mL), B. 
breve R0070 (0.321ogio CFU/mL), and B. bifidum R0071 (0.11 loglo CFU/mL) was not 
significant (p<0.05). 
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When comparing the effect of the strains at each sampling day, at days 6 and 12, B. 
breve R0070 has a significantly higher count compared to B. infantis R0033, and, at day 15, 
both B. breve R0070 and B. longum R0175 had significantly higher counts than B. infantis 
R0033 (p<0.05). The higher count observed in B. breve R0070 and B. longum R0175 can be 
explained by the slightly higher inoculation level at day 0 for B. breve R0070 (8.69 loglo 
CFU/mL) and B. longum R0175 (8.521og10 CFU/mL) when compared to B. infantis R0033 
(7.93 loglo CFU/mL) although these inoculation levels were not significantly different than 
one another. The more pronounced reduction in the log count observed in B. infantis R0033 
over the storage time might contribute to the differences observed at day 12 and 15 as well. 
Figure 2 shows that Bifidobacterium strains used in this study survived after 4 hours 
treatment with simulated pH 3.0 gastric juice at 37°C. Survivability following the simulated 
gastric juice treatment is compared to the counts in the milk for that sampling day. The 
interaction between the storage time and the strains was significant (p<0.05). When 
comparing the effect of the storage time for each strain, B. breve R0070 showed significantly 
better survival in simulated gastric juice at day 12 and 15, with 110.39% survivability and 
110.11 %survivability respectively, compared to day 0 (102.21 %) and 6 (101.61 %). No 
significant differences in the survivability were observed in B. infantis R0033, B. longum 
R0175 and B. bifidum R0071 over the storage period. When the effect of the strains was 
compared on each sampling day, similar survivability rate were observed at each sampling 
day among each strains. For example, at day 0, no significant differences (p<0.05) were 
observed among each strain and the same trend was observed at day 6, 12 and 15. 
Survivability of Bifidobacterium strains after 4 hours of treatment with 1 % (w/v) 
simulated bile solutions in 37°C water bath is illustrated in Figure 3. The interaction between 
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the storage time and the strains was significant (p<0.05). When comparing the effect of 
storage time on the percent survivability of each Bifidobacterium strains, at day 15, 
survivability for B. bifidum R0071 (91.42%) was reduced significantly compared to day 0 
(99.45%), 6 (101.03%) and 12 (100.89%) after the treatment with simulated bile solutions. 
Survivability for B. infantis R0033, B. longum R0175 and B. breve R0070 were not 
significantly different over the 15 days storage period (p<0.05). Differences were observed at 
day 15 when comparing the strains effect on each sampling day. At day 15, B. bifidum R0071 
(91.42%) showed a significantly lower percent survivability compared to B. infantis R0033 
(101.08%), B. longum R0175 (101.31%) and B. breve R0070 (104.56%), which was not 
observed at day 0, 6 and 12. 
Lactose content in the Bifidobacterium milk samples were measured over the storage 
period. Fresh milk samples were used as control and the results are shown in Figure 4. The 
interaction between the strains and the storage time was significant (p<0.05). The relatively 
straight line observed from Figure 4 for lactose content in control, B. infantis R0033, B. 
longum R0175 and B. breve R0070 samples showed that lactose content was maintained over 
the storage period in these samples. This result indicates that B. infantis R0033, B. longum 
R0175 and B. breve R0070 did not hydrolyze lactose when they were inoculated into milk 
and stored at 4°C for 15 days. A different trend was observed in milk samples inoculated 
with B. bifidum R0071. At day 3, the lactose content in B. bifidum R0071 milk was slightly 
lower than other samples and from day 6 to day 15, the lactose content in B. bifidum R0071 
was significantly lower than the other treatments (p<0.05). 
Bifidobacterium bifidum R0071 is the only Bifidobacterium strains used in this study 
that expressed lactase activity. This indicated that, with the incorporation of B. bifidum 
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R0071 into milk, the discomfort in lactose maldigestion individuals might be alleviated. 
Therefore, to increase the therapeutic effects obtained from consumption of Bifidobacterium, 
incorporation of B. bifidum R0071 into milk compared to other Bifidobacterium strains used 
in this study is preferable. 
Inoculation of Bifidobacterium at 8loglo CFU/mL showed a relatively stable 
survivability over the storage period. During the simulated gastric juice treatment, growth 
was observed in the Bifidobacterium milk samples. The growth observed was not greater 
than 1 log1oCFU/mL. This might be attributed to the relatively high inoculation level used in 
this study that hinders the growth of Bifidobacterium. Therefore, in the next study, 
inoculation at a lower level was examined to observe the effect of inoculation level on the 
survivability of Bifidobacterium bifidum R0071 in the milk over the 15—day storage period 
and their survivability and growth during the simulated gastrointestinal tract transit treatment. 
Study 2: Effect of Inoculation Levels on Viability of B. bifidum R0071 in Milk and 
during Gastrointestinal Tract Transit 
The interaction between the inoculation levels and the viability over the storage 
period was not significant over the 15—day storage time and after the treatment with 
simulated gastrointestinal tract transit (p<0.05). 
Figure 5 shows the survivability of B. bifidum R0071, inoculated into milk at 4, 5, 
and 6loglo CFU/mL, over the 15—day storage period. The relative log counts for each 
sampling days compared to day 0 for each sample was determined. No significant differences 
were observed among each sample at each sampling day (p<0.05). The increase or decrease 
in the survivability of B. bifidum R0071 inoculated at 3 different levels over the 15—day 
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storage period was not greater than 10%, which is approximately 0.5 loglo CFU/mL, and was 
not significant. The inoculation levels for B. bifidum R0071 used in this study did not affect 
their survivability in milk significantly over the storage period (p<0.05). 
Survivability after simulated gastrointestinal tract transit is presented in Figure 6 and 
7 for B. bifidum R0071 inoculated at 3 different concentrations. As shown in Figure 6, after 4 
hours of treatment with pH 3.0 gastric juice, the survivability of B. bifidum R0071 was not 
affected and slight growth was observed for all treatments at each sampling day. No 
significant differences were observed among each treatment at each sampling day. Storage 
time did not affect the simulated gastric juice survivability of each treatment significantly as 
well (p<0.05). 
Survivability of B. bifidum R0071 (Figure 7) inoculated at 3 different concentrations 
after simulated bile solutions treatments were similar to the results observed in the simulated 
gastric juice treatment. No significant differences were observed among treatments over the 
storage period and at each sampling day (p<0.05). 
Even though the samples were inoculated at lower concentrations compared to the 
first study, no significant growth was observed after treatment with simulated gastric }uice 
and bile solutions at 37°C for 4 hours (p<0.05). B. bifidum R0071 used in this study survived 
the simulated gastrointestinal tract treatment but was not capable to grow in the environment 
even though their optimal growth temperature was presented. 
The changes in the log count observed over the storage period and after treatment 
with simulated gastric juice and bile solutions were less than 10%, which is, 1 loglo CFU/mL. 
Thus, inoculation at the minimal therapeutic dose, 61og~o CFU/mL, into the milk maybe 
sufficient to provide the consumer with the acclaimed health benefits since they survived the 
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storage and gastrointestinal tract transit in a biologically effective dosage. Therefore, in the 
next study, B. bifidum R0071 is inoculated at 6loglo CFU/mL and supplements, whey 
protein concentrate (WPC) and fructooligosaccharides (FOS), were used to examine their 
effects on the survivability of B. bifidum R0071 during storage and simulated gastrointestinal 
tract transit. 
Study 3: Effect of Supplements on the Survivability of B. bi idum R0071 in Milk and 
during Gastrointestinal Tract Transit 
The effects of supplements, WPC and FOS at 2% and 3%, compared to the control on 
the survivability of B. bifidum R0071 over the 1 S—day storage period are presented in Figure 
8. The interactions between the samples and the storage time were significant (p<O.OS). The 
control, WPC 2% (WPC2) and WPC 3% (WPC3) samples exhibited no significant changes 
in the log count during the 1 S—day storage period. However, the survivability of samples 
supplemented with 2% FOS (FOS2) or 3%FOS (FOSS) decreased during the storage time 
and at day 12 (5.44 login CFU/mL, S .2 S loge o CFU/mL) and 1 S (S .11 loge o CFU/mL, 5.22 
login CFU/mL), the viable count of B. bifidum R0071 in FOS2 and FOS3 were significantly 
lower than their inoculated level (6.13 login CFU/mL, 6.14 login CFU/mL). 
At each sampling day, no significant differences were observed among control, 
WPC2 and WPC3. At day 12 and 1 S, FOS2 and FOS3 showed a significantly lower 
survivability compare to the control, WPC2 and WPC3 samples (p<O.OS). Reduction of 
approximately 1 login CFU/mL were observed in both FOS2 and FOS3 samples over the 1 S—
day storage period. 
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Interactions between the supplements and the B. bifidum R0071 viability over the 
storage period after the simulated gastrointestinal tract transit treatment were not significant 
(p<0.05). Supplementation with WPC and FOS did not affect the survivability of B. bifidum 
R0071 significantly in the simulated gastric juice, as shown in Figure 9 (p<0.05). All samples 
survived the simulated gastric juice treatment and no significant differences were observed 
among each sample over the storage period. WPC and FOS used in this study did not 
promote growth of B. bifidum R0071 when treated with simulated gastric juice at their 
optimal growth temperature, 37°C. 
Effects of supplements on the survivability of B. bifidum R0071 in the simulated bile 
solutions are shown in Figure 10. Over the storage period, the effect of storage time did not 
affect the survivability of B. bifidum R0071 during simulated bile solutions treatment and nQ 
significant differences were observed (p<0.05). When comparing the effect of treatments at 
each sampling day, at day 0, 6 and 12, the survivability toward simulated bile solutions 
treatment were not different significantly. At day 15, FOS2 samples showed a significantly 
better survival compare to the control samples with no supplements added. Even though 
differences were observed at day 15 among the samples, the differences were not greater than 
11%, which is less than 1 loglo CFU/mL. 
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DISCUSSION 
Effect of Bifidobacterium Strains and Inoculation Levels in Milk 
Storage stability 
As shown in Figure 1, no significant growth or reduction was observed for all the 
Bifidobacterium strains used in this study when inoculated into milk at approximately 8 loglo 
CFU/mL and stored at 4°C for 15 days (p<0.05). Similar results were observed for B. bifidum 
R0071 inoculated at 4, 5 and 6loglo CFU/mL (Figure 5). The storage temperature, 4°C, used 
in this study is not the optimum growth temperature for Bifidobacterium, therefore, no 
growth would be expected during the storage period (Leahy and others 2005). Survival rather 
than growth is desirable because when Bifidobacterium grows, metabolites, such as lactic 
acid and acetic acid, will be produced (Rasic and Kurmann 1983; Modler and others 1990). 
The production of acids might alter the pH of the milk and consequently affect the sensory 
properties of the milk. Reduction in counts of Bifidobacterium over the storage period is not 
desirable as well. If the Bifidobacterium lose their viability over the storage period, the milk 
might not be able to deliver a sufficient amount of Bifidobacterium to the consumer to 
achieve the required therapeutic dose, which is greater than 6loglo CFU/mL (Kurmann and 
Rasic 1991). 
The results obtained from these studies (Figure 1 and Figure 5) agreed with those of 
Hughes and Hoover (1995), who found that cultures of B. bifidum, B. longum, B. breve and B. 
angulatum inoculated at 6loglo CFU/mL into unfermented skim milk did not show 
significant loss of viability over the 15—day storage period under refrigerated conditions 
(p<0.05). Similarly, Sanders and others (1996) reported that viability of Bifidobacterium 
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BG9 inoculated at 7loglo CFU/mL into 1.5%fat milk was not affected during a 21—day 
incubation period at 4°C. 
Commercially available milk inoculated with Bifidobacterium and L. acidophilus 
(strains not specified) stored at 4 ~ 0.5°C were studies by Shin and others (2000b). A 
significant reduction (0.41og10 CFU/mL) in the Bifidobacterium population was observed in 
the commercial milk samples 3 days prior to the expiration date and the reduction increased 
to 71% (0.5 login CFU/mL) at the time of the product expiration. Even though the reduction 
was significant in this study, the log reduction observed was not greater than 1 loglo CFU/mL 
until 6 days after the milk expired. Therefore, results from the study by Shin and others were 
considered similar to the results obtained in our study. 
Survivability in simulated gastric juice 
Being able to survive the acidity in the gastric juice produced in the human stomach 
is an important characteristic of Bifidobacterium to be used as probiotic dietary adjuncts. 
Several studies have been conducted in which the effect of the acid simulating gastric 
environment on the survivability of Bifidobacterium and other lactic acid bacteria were 
examined (Conway and others 1987; Berrada 1991; Clark and others 1993; Lankaputhra and 
Shah 1995; Charteris and others 1998; Lian and others 2003). Bifidobacterium strains used in 
this study survived the 4 hours of treatment with simulated pH 3.0 gastric juice prepared 
according to Lian and others (Figure 2 and Figure 6). This result agreed with the study 
conducted by Clark and others (1993). Clark and others observed that B. infantis, B. longum, 
B. bifidum and B. adolescentis in neomycin-paromomycin-nalidixic acid-lithium chloride 
(NPNL) broth survived pH 3.0 simulated gastric juice for 3 hours at 37°C. In addition to pH 
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3.0, they also showed that when treated with pH 2.0 simulated gastric juice, B. infantis, B. 
longum and B. adolescentis maintained their viability as well but B. bifidum lost their 
viability after one hour. 
Results from study conducted by Lankaputhra and Shah (1995) were different than 
our study for some of the strains used. At pH 3.0, B. bifidum 1900 and 1901, B. breve 1930 
and B. longum 20097 showed a rapid reduction in the viable counts over the 3 hours 
incubation period at 37°C, which contradicted the results observed in our study. However, 
survivability of B. infantis 1912 and B. longum 1941 were similar to the results observed in 
our study. The differences in the results observed might be due to the different methodology 
applied. An acidic environment was created by adjusting the pH of the culture broth with 5 N 
HCl in Lankaputhra and Shah's study, which is different than. our study where 10 mL of the 
milk samples were added into 10 mL pH 3.0 gastric juice. Addition of milk into the gastric 
juice in our study increased the pH of the gastric juice to 6.56. With the pH close to neutral, 
the survivability of the Bifidobacterium was improved. 
In addition to increasing the pH of the gastric juice, Charteris and others (1998) 
showed that with the addition of milk protein, the tolerance of B. infantis and Lactobacillus 
casei to simulated gastric juice increased to 100%. Similar results were observed by Conway 
and others (1987) with the addition of skim milk to lactic acid bacteria treated with human 
gastric juice. Charteris and others (1998) suggested that the buffering capacity of milk 
protein and the capability of milk protein to inhibit protease activity in vivo might help to 
protect the Bzfidobacterium during upper gastrointestinal tract transit and thus increase their 
survivability. 
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From Figure 2, over the storage period, Bifidobacterium showed a slight 
improvement in viability after treatment with gastric juice for 4 hours. Bifidobacterium might 
have utilized the lactose in the milk and produced lactic acid. The production of the lactic 
acid decreased the pH of the milk and Bifidobacterium might have adapted to the lower pH 
gradually. Adaptation to the lower pH might have helped to improve their viability when 
exposed to the gastric juice. 
Survivability in simulated bile solutions 
To be used as dietary adjuncts, Bifidobacterium must survive through the bile 
concentrations produced in the human small intestine. Effects of bile solutions on 
Bifidobacterium during gastrointestinal txact transit .were studied by several researchers (R.ao 
and others 1989; Ibrahim and Bezkorovainy 1993; Clark and Martin 1994; Lankaputhra and 
Shah 1995; Charteris and others 1998; Lee and Heo 2000). Bile solutions used in our study 
were prepared according to Lian and others (2003) and Clark and Martin (1994). The 
concentration of bile solutions used was 1 %. According to Ibrahim and Bezkorovainy (1993), 
normal bile concentrations in the human small intestine is 0.06%, and 2% is the maximal 
concentration found in the human small intestine during the first hour of digestion of food. 
After treatment with 1 %bile solutions for 4 hours at 3 7°C, log counts for the 
Bifidobacterium strains used in our study did not vary more than 1 loglo CFU/mL (Figure 3 
and Figure 7). Lankaputhra and Shah (1995) showed that when 1%bile salts were added into 
the reconstituted nonfat dry milk supplemented with glucose, yeast extract and L-cysteine 
hydrochloride (NGYC) broth containing Bifidobacterium, B. infantis 1912, B. breve 1930 
and B. l ongum 1941 survived the treatment after 3 hours at 3 7°C, which agreed with the 
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results observed in our study. However, the results for B. bi~dum conflicted with the results 
obtained in our study. The B. bifidum 1900 strains used in Lankaputhra and Shah's study 
showed a 1 loglo CFU/mL reduction after 3 hours in their study and, rapid decline in the log 
count was observed in B. bifidum 1901 strains after 1 hour and a 4loglo CFU/mL reduction 
was observed after 3 hours. 
Results from the study conducted by Clark and Martin (1994) were different than the 
results observed in our study. Clark and Martin showed that B. infantis, B. adolescentis and B. 
bifidum did not survive the bile solutions treatment and only B. longum used in their study 
survived bile solutions treatment. The differences observed are probably due to the different 
methodology applied. Clark and Martin incubated 1 mL Bifidobacterium containing broth 
into 10 mL of 2%bile solutions for 12 hours. The higher bile concentration used, the longer 
incubation time and the different amount of bile solutions applied in Clark and Martin's 
study might have contributed to the differences in the results. 
Bifidobacterium's ability to survive the bile salts treatment might be due to the 
presence of bile salt hydrolase in the cell. Lepercq and others (2004) showed that living 
Bifidobacteria animalis DN-173 010 exhibited bile salt hydrolase activity in the 
gastrointestinal tract of the pig. With the presence of bile salt hydrolase, bile salts in the 
simulated bile solutions used in our study were hydrolyzed. Therefore, without the action of 
the bile salts in the solutions, Bifidobacterium were able to survive the 4 hours simulated bile 
solutions treatment. 
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Lactose Content 
The presence of lactase activity in B. bifidum R0071 milk observed in this study was 
similar to that in the study conducted by Passerat and Desmaison (1995}, which showed that 
lactase activity, was observed in B. bifidum fermented milk. B. bifidum fermented milk was 
added into 20 mL of 0.1 M phosphate buffer and adjusted to pH 6.5. The samples were 
incubated at 40°C, and, after 2 hours, lactose content was reduced from 2.96 g/100g to 1.35 
g/ 100g. 
A study conducted by Jiang and Savaiano (1997) demonstrated lactase activity in B. 
longum B6 in an in vitro fermentation process simulating ileostomy effluent containing 3.5% 
lactose. The results observed in Jiang and Savaiano disagreed with the results from our study. 
The difference in the results can be explained by the different gr©wth condir.ic~~r~s used in the 
studies. The B. longum RO l 75 used in this study was grown in MRS broth with 0.05 
cysteine supplement. However, the B. longum B6 used in Jiang and Savaiano's study was 
grown in MRS broth supplemented with lactose as the sole carbohydrate source to adapt B. 
longum B6 to utilize lactose and express lactase activity. Therefore, lactase activity was 
observed during the fermentation process. 
The adaptation of B. longum B6 to express lactase activity is further demonstrated in 
another study conducted by Jiang and others (1996). Jiang and others showed that when B. 
longum B6 was grown with lactose as the sole carbohydrate source, the ~3-galactosidase 
activity was higher (1.411 U/mL) compared to the B. longum B6 that was grown with both 
lactose and glucose (0.074 U/n~L) as carbohydrate sources. They concluded that when B. 
longum is grown in medium containing only lactose as the sole carbohydrate source, a higher 
lactase activity is induced. 
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Effect of Supplements on the Survivability of B. bifidum R0071 in Milk 
To increase the viability of Bifidobacterium in a food system, supplements that act as 
Bifidobacterium growth promoters can be added. Whey protein concentrate (WPC) and 
fructooligosaccharides (FOS) are widely used in the dairy industry to enhance the growth of 
Bifidobacterium in dairy products. Studies with 2% and 3%WPC or FOS supplementation 
have been shown to improve the survivability of Bifidobacterium in yogurt (Dave and Shah 
1998; Shin and others 2000a; Bruno and others 2002; Martin—Diana and others 2003; Akalin 
and others 2004; Janer and others 2004). Even though many studies have focused on the 
supplement effects on the viability of Bifidobacterium in food products, no published studies 
have examined the effects of WPC and FOS on the survivability of Bifidobacterium during 
gastrointestinal tract transit. 
Whey protein concentrate 
In our study, over the storage period, treatments with WPC supplement had a similar 
survival rate compared to the control treatment. However, treatments with FOS supplement 
showed a reduction in log count over the storage period at 4°C (Figure 8). The similar 
survivability observed in the WPC supplemented samples to the control was desirable and 
was similar to the study conducted by Dave and Shah (1998) with yogurt. Dave and Shah 
supplemented whey protein concentrate into yogurt and the survivability of Bifidobacterium 
in the yogurt samples were maintained at 6loglo CFU/mL over the 35 days storage period at 
4°C. 
Janer and others (2004) observed a significantly better growth, 2 logo CFU/mL, 
when skim milk is supplemented with WPC and incubated at 37°C for 24 hours compared to 
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the control with no supplements. However, no significant growth was observed in our study 
when B. bifzdum R0071 milk samples with wPC supplement were stored at 4°C for 15 days. 
This can be explained by the different incubation temperature used in our study. The 
incubation temperature, 4°C, is not the optimum growth temperature for BifidobacteYium, 
thus, no growth was observed in our samples. 
Fructooligosaccharides 
The decrease in viability observed in FOS supplemented treatments were different 
than the results obtained by Akalin and others (2004). Akalin and others supplemented 
yogurt with FOS and the viability of the Bifidobacterium increased over the 28—day storage 
time at 4°~ compared to the control samples without FOS. Shin and others (2,O~~J~ also 
showed that with the addition of FOS, growth of Bifidobacterium was enhanced in the skim 
milk when incubated at 37°C for 48 hours, and increased viability was observed when stored 
at 4°C for four weeks. 
The reduction in the microbial counts during the storage period might be attributed to 
the utilization of FOS by B. bifidum R0071. Bielecka and others (2002) showed that 
Bifidobacterium has a higher growth rate when grown in FOS and oligofructose medium 
compared to the control medium with lactose as the main carbohydrate source. As 
Bifidobacterium grows, production of lactic acid and acetic acid from the fermentation of 
FOS might have inhibited or reduced the viability of Bifidobacterium itself over the storage 
period and thus contributed to the lower counts in the FOS—supplemented samples. 
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Figure 2 Percent survivability of Bifidobacterium strains in milk stored for 15 days at 4°C 
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Figure 5 Percent survivability relative to day 0 of Bifidobacterium bifidum R0071 inoculated 
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Figure 6 Percent survivability of B. bifidum R0071 inoculated into milk at 3 different 
concentrations and stored for 15 days at 4°C after 4 hours simulated gastric juice treatment 
56 
120 
100 
_~ 
— 80 
■~ 
~~ 60 
"' 40 
20 
0 
®4 B.bi w 5 B.bi 6 B.bi 
.~ 
D`a`>`>~>`>~ . ~. . . ~ 
D > a > > a . ~. ~. . 
> > > > > > . ~. ~. ~ D > > > > . < < < < < < 
D a > a f > 
t < < < a < 
a > a > a 
< < < < < t 
p > > > > > 
< < t < t t 
p a > a > a 
t t < s < < 
p i>~>~aia~a~ 
b > a a > > 
< s < < < < 
D > > > a > 
< < t < < t 
> > a > > 
< < ~ r < < 
p > a > > > 
< • ~ < < < 
D > > > > > 
t < < < < < 
D > a a > > 
. ~.. << 
D > > > > > . . ~<<. 
. > a > a > . . ~... ~ > > > > > . <<. ~. 
< < <. < < 
D > > > a > 
c < < < ♦ < 
> > > > > > 
< < < < < < 
r > > > > > 
p ~> t>~>~>~>~ ~ s < < < < 
> > > > > > 
s ~ < < < < > > a > > > 
. t < < < < 
> > > > > a 
a < < . < < 
> > > > > > 
< < < < < < 
0 
. . . . . . 
> > a > > > ~. . . << 
a > > > > > <<. . . ~ 
> > a a > > < < < < < < 
> > > > > > 
t < < < < < 
a > > > a > 
< < < c < < 
> > > a > > 
< t t s < < 
> > > > > > 
< < < < c t 
> > > > > a 
< < < < < < 
> > ~ > > > 
< < < < < 
> > > > > > 
t < < c < < 
> > > > > > 
< < < < < < 
> > > > > > 
< < < < < < 
> a > > > > 
< < < < < r 
a > > ) > > 
< ( < < < < 
> > > > > > .. . . << 
a a > > a > ~.. . . . 
> > > > a > .... . ~ 
> a > > > . .. ~. .. >>>>>> . <<<. ~ >>>>a> <<<. . . 
> > > a a > . . . <<< 
> > > > > a 
< a < < < < 
> > a a > a . . . . . > > > > > <. ~.. < > > > > > > < < < < < < > > > > > > < < <. <. 
> a > > > , < < < < < < 
> > > a > > 
< < t < < < 
> > > > a > 
t < < r < c 
> > > > > a 
c < s < c 
> > > > > > 
< < < < < e 
> > > > > > 
< < t c < < 
> a > > a > 
< < < < < < 
> a > a > a 
< t < < < < 
> > > a > > 
< < ~ < < < 
a > > > > > 
~ ~ r < < < 
> > > > > > 
. ~ ~ < < < 
a > > > a > 
< < < < < < 
> > > > a > 
< ~ < t < < 
> > > > > ) 
< < t < < < 
6 
Time (day) 
12 
> > . > > > ~ <<. ~. a>>a> . <<<<. 
> > > > > <<. <<< > > > > > < < < < < < 
a > > > > 
t t < < < < 
> > > > > 
< < < r < < 
a > > > > 
< < < < t < 
> > > > > 
< < < < < < 
> > > a > 
< < < < < < 
> a > a > 
< < < < < < 
> > > ) > 
c < < < t 
> > a > a 
t < < < < < 
> > > > > > 
< t < < s r 
> > > > > > 
< < < < < < 
> > > > > a 
< < < < < t 
> a > > a > . . . . << 
> > > > > . ... << > . a > a > . ~... >. >a> . . <<. . >>>>. <<. <<. 
> > > > > > . ~. ... 
a > > > > > ~..... 
> > a > > > 
t < < < s ~ 
> a > > a a < < < < <. > > a a > > < <..< < > a > > > > < < <. < < > > > > > a < < < < < < > > > > a > < < <. ~. 
a > > > > > 
t < < < < t 
> > > a > > 
< < < < s < 
> > > > > > < < < < < < 
a > > > > > 
< < < < < < > > > > > > < < < < < < 
> > > > > > < < < c < < 
> a > a > > 
< < < < < < 
> > > > > > < c r < < < 
> > > a > > 
< < < < < s 
> > a > a > 
< < < < < < > > > > > > 
< t t ( < t 
> > > > ) > 
< < < < < t 
15 
Figure 7 Percent survivability of B. bifidum R0071 inoculated into milk at 3 different 
concentrations and stored for 15 days at 4°C after 4 hours simulated bile solutions treatment 
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Figure 8 Viability of B. bifidum R0071 with added supplements in milk during 15 days 
storage period at 4°C 
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and stored for 1 S days at 4°C after 4 hours simulated gastric j uice treatment 
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Figure 10 Percent survivability of B. bifidum R0071 inoculated into milk with supplements 
and stored for 15 days at 4°C after 4 hours simulated gastric juice treatment 
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CONCLUSION 
The Bifidobacterium strains, B. bifidum R0071, B. breve R0070, B. infantis R0033 
and B. longum R0175 used in this study survived over the 15—day storage period. B. bifidum 
R0071 is the only Bifidobacterium strain used in this study that hydrolyzed lactose. Different 
inoculation level did not affect the viability of B. bifidum R0071 significantly over the 15— 
day storage study. Whey protein concentrate (WPC) and fructooligosaccharides (FOS) 
supplements used in this study did not increase the viability and growth of the B. bifidum 
R0071 significantly compared with those of the control. 
The changes in the log count during the storage period and after the treatment with 
simulated gastric juice and bile solutions were not greater than 1 loglo CFU/mL in a113 
studies, which showed that milk, can be used as an effective carrier for the delivery of 
Bifidobacterium into the human gut. Inoculation of Bifidobacterium at 6loglo CFU/mL into 
milk without WPC and FOS supplement is recommended. A serving size for milk is 
approximately 236 mL, and, at this inoculation level, consumer would be able to obtain 
approximately 8 loglo CFU, which is the recommended therapeutic dose, in 1 serving of milk. 
Simulated gastrointestinal tract transit used in this study was not performed under 
anaerobic conditions, thus, oxygen stress might affect the viability of Bifidobacterium during 
the treatment. In addition, the amount of simulated gastric juice and bile solutions used to 
treat the milk samples in this study were conducted with 1:1 ratio, which might not be the 
accurate amount of gastric juice and bile solutions secreted in human gastrointestinal tract. 
Therefore, a different survivability might be observed when Bifidobacterium milk samples 
were consumed in human clinical trials. 
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Sequential application of simulated gastric juice and bile solutions, which is more 
comparable to the human gastrointestinal tract transit, can be conducted. The survivability of 
Bifidobacterium in the simulated bile solutions might be affected after treatment with 
simulated gastric juice. Clinical studies with human subjects can be conducted as well to 
compare the results from the simulated gastrointestinal tract transit performed in this 
experiment to the results from the in vivo study. Clinical studies can further provide 
information to researchers regarding the survivability of Bifidobacterium during 
gastrointestinal tract transit. 
During the simulated gastrointestinal tract transit, samples were incubated at 3 7°C, 
which is the optimal growth temperature for Bifidobacterium. Incubation at this temperature 
might stimulate the growth of Bifidobacterium in the samples and lactose might be utilized 
by Bifidobacterium as the energy source. Therefore, lactose measurement can be conducted 
after the 4—hour simulated gastrointestinal tract transit to obtain an estimation of an in vitro 
lactose utilization rate during the gastrointestinal tract transit. 
Other supplements that were studied and presented positive effects, such as lactulose, 
inulin, acid casein hydrolysate, tryptone and caseinomacropeptide, can be studied to examine 
their effects on enhancing the survivability and growth of Bifidobacterium in the milk over 
the storage period and during the simulated gastrointestinal tract transit (Modler and others 
1990; Gibson and others 1995; Dave and Shah 1998). Effects of a combination of different 
supplements on the survivability of Bifidobacterium can be conducted to obtain a good and 
effective combination of supplements as well. 
Sensory quality of the food is important. With the incorporation of Bifidobacterium 
into the milk, the sensory properties of the milk might be affected. Addition of supplements 
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into the milk can also affect the sensory properties of the milk as well. Therefore, sensory 
studies should be conducted to examine the effects of the Bifidobacterium and the 
supplements on the aroma and flavor of the milk. 
Bifidobacterium survived in the milk throughout the shelf life of the milk and after 
the simulated gastrointestinal tract transit treatment. Therefore, milk can be used as a carrier 
medium to deliver Bifidobacterium and their therapeutic health benefits to the society. 
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APPENDIx A 
Effects of Supplements on the Survivability of Bi idobacte~ia longum in Milk 
B. longum R0175 was inoculated into milk samples at 109 CFU/mL and stored at 4°C 
for 15 days. Ascorbic acid, cysteine or ascorbic acid plus cysteine were added into B. longum 
R0175 milk samples at 0.05% concentration. Microbial analysis and lactose utilization were 
conducted at 3 day intervals for 15 days. Survivability during gastrointestinal tract transit was 
conducted with pH 2.0 gastric juice and 1 %bile solutions at day 0, 6, 12 and 15. B. longum 
RO 175 milk samples (1 mL) were added into 9 mL gastric juice or 9 mL bile solutions and 
incubated in 37°C water bath for 4 hours. Samples were plated on MRSC agar and incubated 
anaerobically at 37°C for 72 hours. 
Over the 15—day storage time, the survivability o f B. longum RO 17 5 was maintained 
at over 8 logs o CFU/mL (Figure 1). Supplements with cysteine and ascorbic acid did not 
show any effect on the growth or reduction of B. longum R0175 in milk over the storage time. 
When treated with gastric juice and bile solutions, reduction in log counts was observed in all 
samples. After 4 hours of treatment with pH 2.0 gastric juice, B. longum R0175 in all milk 
samples except cysteine supplemented samples, did not survive, as shown by counts of less 
than 1 logl o CFU/mL (data not shown). cysteine supplemented B. longum R0175 milk 
samples survived the gastric juice treatment and at day 15, counts of B. longum R0175 were 
at 5.13 loglo CFU/mL. Bile solutions treatment affected the viability of B. longum R0175 in 
milk. At day 1 S, all milk samples had less than 1 logs o CFU/mL after treatment with 1 %bile 
solutions for 4 hours (data not shown). 
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Samples supplemented with cysteine showed a reduction in lactose content at day 9, 
and at day 15, 53% reduction in lactose content was observed (Figure 2). B. longum R0175 
milk samples have a lower lactose content compared to the control milk samples with no B. 
longum R0175 inoculated over the storage time. 
Sensory properties of the milk samples were examined at each sampling day by 
sniffing the aroma of the milk. Undesirable sulfur odor was observed for the milk samples 
supplemented with cysteine. Samples supplemented with ascorbic acid have a stronger sour 
aroma compared to the control sample with no supplement over the storage time. 
Supplements did not enhance the viability of B. longum R0175 in milk samples over 
the storage time. cysteine supplement enhanced the viability of B. longum R0175 when 
treated with pH 2.0 gastric juice. However, due tQ the undesirable aroma that affected the 
sensory property of the milk, we did not proceed with this supplement. In addition, curding 
was observed in all samples after 15 days of storage. Therefore, a lower inoculation level is 
preferred to preserve the sensory quality of the milk. 
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Figure 1 Survivability of Bifidobacteria longum R0175 with added supplementsa in milk 
stored for 15 days at 4°C 
aNS = No supplement, AA =Ascorbic acid supplement, Cys =Cysteine supple lent, 
A.A+C =Ascorbic acid and cysteine supplements 
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Figure 2 Lactose content in milk samples inoculated with Bifidobacteria longum R0175 
with added supplementsa during the 15 days storage time. 
aControl = Uninoculated Milk NS = No supplement, AA =Ascorbic acid supplement, 
Cys =Cysteine supplement, AA+C =Ascorbic acid and cysteine supplements 
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APPENDIX B 
Quality of Milk Packaged in Polylactic Acid and Polyethylene Terephthalate Bottles 
Environmental concerns related to the use of plastic materials for food containers 
have contributed to the development of packaging materials from renewable resources that 
are biodegradable. Polylactic acid (PLA) is a plastic made from corn sugars and is cost 
competitive with current petroleum-based plastics. Although PET (polyethylene terephthalate) 
bottles are widely used for food packaging, these bottles are non-biodegradable. Food-
package interactions can influence the nutritional, flavor, and microbial quality of the food 
products. Light penetration can also have a significant impact on sensory and nutritional 
quality through the degradation of riboflavin and formation of light-sir"ack flavor. 
The objective of this study was to compare the microbiological, sensory, and nutritiv e 
quality of milk packaged in PLA and PET bottles. Moisture migration in PLA and PET 
bottles were examined as well. 
Milk was packaged in PLA or PET bottles. Milk samples stored at 4 and 10 °C were 
analyzed using standard plate count methods to monitor microbiological quality. Milk 
samples were stored in light or dark (control) for 4 hours to determine effects of light 
exposure and packaging material and sensory quality and riboflavin content. Sensory quality 
was evaluated using triangle tests to compare alI combinations of light exposure and 
packaging treatment. Moisture migration was conducted by filling PLA and PET bottles with 
S OOg of water and stored at 4 and 10°C for 5 weeks. 
Storage time, but not packaging material had a significant effect on microbial growth. 
Microbial counts exceeded 10~ CFU/mL after 14 and 21 days, when stored at 10 °C and 4 °C, 
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respectively (Figure 1). As shown in Table 1, of the light exposure and packaging treatment 
combinations evaluated, sensory panelists were only able to detect differences in light-
exposed and control milk packaged in PET bottles. Table 2 showed that light exposure 
reduced riboflavin content from 0.19 to 0.16 mg/ 100 mL milk. However, packaging material 
did not affect riboflavin content. PLA bottles showed a higher loss of weight compare to PET 
bottles when stored at 10°C. After 5 weeks storage, PLA bottles lost 5.73 g and 0.90 g, when 
stored at 10°C and 4°C, and PET bottles lost O.00g and 0.47 g, respectively (Figure 2). 
Comparison of PLA and PET bottles for milk resulted in no differences in 
microbiological, sensory, or nutritive quality. PLA is an environmentally friendly alternative 
to PET for packaging milk. 
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Table 1 Effect of packaging material and light exposure on sensory quality of  milk 
Constant Factor Treatment Variable Differences detected by 
Panelists (a <0.05) 
PET Bottles Light vs Dark Yes 
PLA Bottles Light vs Dark No 
Light Exposure PLA vs PET No 
Dark PLA vs PET No 
Table 2 Effect of packaging material and light exposure on riboflavin contents of milk 
Treatment 
Packaging Material Light Dark Average 
PLA 0.15 0.20 0.18 
PET 0.16 0.18 0.17 
Average 0.16 0.19 
a mg/100 mL milk 
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Figure 2 Weight loss from PLA and PET bottles filled with water during storage at 4 and 
10°C 
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